[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 221
6. Ross AH, Kennedy CT, Collins C, Harrad RA: The use of imiquimod in the treatment of periocular tumours. Orbit; 2010 Apr;29(2):83-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two patients were diagnosed with basal cell carcinoma of the eyelid, one patient with actinic keratosis, one with intraepidermal squamous cell carcinoma (Bowen's disease) and one patient had concomitant squamous cell carcinoma and intraepidermal squamous cell carcinoma.
  • In our experience, it is a safe and effective treatment for periocular lesions, including actinic keratosis, intraepidermal squamous cell carcinoma, basal cell carcinoma and squamous cell carcinoma.
  • To our knowledge, this is the first published description of the successful use of 5% Imiquimod in treating moderately differentiated squamous cell carcinoma of the eyelid.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Eyelid Neoplasms / drug therapy. Keratosis, Actinic / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Aged. Bowen's Disease / drug therapy. Bowen's Disease / pathology. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Female. Humans. Male. Middle Aged. Ophthalmic Solutions. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20394545.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Ophthalmic Solutions; 99011-02-6 / imiquimod
  •  go-up   go-down


7. Wilkins K, Dolev JC, Turner R, LeBoit PE, Berger TG, Maurer TA: Approach to the treatment of cutaneous malignancy in HIV-infected patients. Dermatol Ther; 2005 Jan-Feb;18(1):77-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients infected with human immunodeficiency virus (HIV) have an increased risk of developing skin cancers.
  • This article will review and discuss management issues for the following malignancies: lymphomas, malignant melanoma, basal cell carcinoma, squamous cell carcinoma, and Kaposi's sarcoma.
  • [MeSH-major] HIV Infections / complications. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy
  • [MeSH-minor] Carcinoma, Basal Cell / complications. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Humans. Lymphoma / complications. Lymphoma / diagnosis. Lymphoma / therapy. Melanoma / complications. Melanoma / diagnosis. Melanoma / therapy. Sarcoma, Kaposi / complications. Sarcoma, Kaposi / diagnosis. Sarcoma, Kaposi / therapy

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842615.001).
  • [ISSN] 1396-0296
  • [Journal-full-title] Dermatologic therapy
  • [ISO-abbreviation] Dermatol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 148
  •  go-up   go-down


8. Dotto J, Pelosi G, Rosai J: Expression of p63 in thymomas and normal thymus. Am J Clin Pathol; 2007 Mar;127(3):415-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The DeltaN-p63 isoforms of p63, which are believed to behave as oncogenes, are expressed in squamous cell carcinoma, basal cell carcinoma, and transitional cell carcinoma.
  • We studied 66 cases of thymoma (1 type A, 8 type AB, 12 type B1, 19 type B2, 12 type B3, and 14 type C/thymic carcinoma) and 10 specimens of normal human thymus arranged in tissue microarrays.
  • All thymomas (including thymic carcinomas) were positive for p63 regardless of type.
  • [MeSH-major] DNA-Binding Proteins / biosynthesis. Thymoma / metabolism. Thymus Gland / chemistry. Thymus Neoplasms / metabolism. Trans-Activators / biosynthesis. Tumor Suppressor Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17276940.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


9. Szeimies RM, Morton CA, Sidoroff A, Braathen LR: Photodynamic therapy for non-melanoma skin cancer. Acta Derm Venereol; 2005;85(6):483-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for non-melanoma skin cancer.
  • Photodynamic therapy is a treatment modality that has been shown to be effective mainly for the dermato-oncologic conditions: actinic keratosis, Bowen's disease, in situ squamous cell carcinoma and basal cell carcinoma.
  • For actinic keratosis and basal cell carcinoma, methyl aminolevulinate-photodynamic therapy is already approved in Europe, Australia and New Zealand, and is now also approved for actinic keratosis in the US.
  • [MeSH-major] Photochemotherapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Bowen's Disease / drug therapy. Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Humans. Photosensitizing Agents

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16396794.001).
  • [ISSN] 0001-5555
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Photosensitizing Agents
  • [Number-of-references] 51
  •  go-up   go-down


10. Garcia C, Poletti E, Crowson AN: Basosquamous carcinoma. J Am Acad Dermatol; 2009 Jan;60(1):137-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basosquamous carcinoma.
  • BACKGROUND: Basosquamous carcinoma is considered an aggressive type of basal cell carcinoma (BCC) with an increased risk of recurrence and metastases.
  • METHODS: This is a narrative review based on a MEDLINE search of articles in English and a manual search of popular dermatology textbooks to define basosquamous carcinoma, its incidence, clinical behavior, and treatment of choice.
  • RESULTS: There are no specific clinical features to distinguish basosquamous carcinoma from other BCC types and the diagnosis is made only after biopsy.
  • There are several histologic definitions of basosquamous carcinoma ranging from a characteristic combination of BCC and squamous cell carcinoma with or without a transition zone, to any BCC with evidence of keratinization.
  • The authors confine the use of the term to an infiltrative growth BCC with areas of keratinization and/or intercellular bridge formation in the setting of a prototypic proliferative stromal reaction.
  • The term "metatypical basal cell carcinoma" is considered a synonym but its use is discouraged for the reasons outlined.
  • The reported incidence of basosquamous carcinoma ranges from 1.2% to 2.7%.
  • The aggressive biological behavior and clinical course distinguish basosquamous carcinoma from other forms of BCC.
  • CONCLUSION: The terminology surrounding basosquamous carcinoma is confusing and there is a need for more uniform language.
  • Data regarding the incidence, recurrence, and metastasis rates of basosquamous carcinoma are based mostly on retrospective series with a limited number of cases.
  • We conclude that although the incidence of basosquamous carcinoma is unknown, there is a literature precedent suggesting more aggressive biological behavior.
  • We believe that complete surgical excision is the preferred approach, and that basosquamous carcinoma is an ideal candidate lesion for Mohs micrographic surgery.
  • [MeSH-major] Carcinoma, Basosquamous. Skin Neoplasms


16. Srikanth V, Fryer J, Venn A, Blizzard L, Newman L, Cooley H, Albion T, Jones G: The association between non-melanoma skin cancer and osteoporotic fractures--a population-based record linkage study. Osteoporos Int; 2007 May;18(5):687-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The association between non-melanoma skin cancer and osteoporotic fractures--a population-based record linkage study.
  • We studied the association between osteoporotic fractures and prior non-melanoma skin cancer (NMSC, a biomarker for cumulative sun exposure).
  • We aimed to study the association between non-melanoma skin cancer (NMSC), a marker of cumulative sun exposure, and osteoporotic fractures in an older cohort.
  • This effect was significant for most fracture subtypes except pelvic and wrist fractures and observed for both NMSC subtypes, squamous cell carcinoma and basal cell carcinoma.
  • Achieving a balance between adequate lifetime sun exposure and protection against its adverse effects (such as fractures and skin cancer) may require assessment of individual risks.
  • [MeSH-major] Fractures, Bone / etiology. Medical Record Linkage. Osteoporosis / complications. Skin Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Fractures.
  • MedlinePlus Health Information. consumer health - Osteoporosis.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2005 May 7-13;365(9471):1621-8 [15885294.001]
  • [Cites] Am J Epidemiol. 1990 Feb;131(2):373-5 [2296988.001]
  • [Cites] J Epidemiol Community Health. 2004 Feb;58(2):142-4 [14729897.001]
  • [Cites] Osteoporos Int. 2005 Jun;16(6):636-41 [15448989.001]
  • [Cites] Am J Clin Nutr. 1995 Mar;61(3 Suppl):638S-645S [7879731.001]
  • [Cites] Public Health Nutr. 2001 Apr;4(2B):547-59 [11683549.001]
  • [Cites] Am J Clin Nutr. 1990 Jun;51(6):1075-81 [2349922.001]
  • [Cites] Osteoporos Int. 2001;12(2):124-30 [11303712.001]
  • [Cites] J Bone Miner Res. 1995 Nov;10(11):1802-15 [8592959.001]
  • [Cites] Osteoporos Int. 2005 Nov;16(11):1425-31 [15744449.001]
  • [Cites] Value Health. 2003 Sep-Oct;6(5):574-83 [14627064.001]
  • [Cites] Cancer Causes Control. 1997 May;8(3):271-83 [9498892.001]
  • [Cites] J Invest Dermatol. 2003 Jun;120(6):1087-93 [12787139.001]
  • [Cites] Aust N Z J Med. 2000 Apr;30(2):209-14 [10833112.001]
  • [Cites] J Clin Endocrinol Metab. 1999 May;84(5):1562-6 [10323380.001]
  • [Cites] Bone Miner. 1994 May;25(2):83-92 [8086854.001]
  • [Cites] N Engl J Med. 1992 Dec 3;327(23 ):1637-42 [1331788.001]
  • [Cites] BMJ. 2005 Apr 30;330(7498):1003 [15860827.001]
  • [Cites] Australas J Dermatol. 1997 Jun;38 Suppl 1:S1-6 [10994463.001]
  • [Cites] J Am Coll Nutr. 2003 Apr;22(2):142-6 [12672710.001]
  • [Cites] Eur J Clin Nutr. 2004 Aug;58(8):1095-109 [15054436.001]
  • [Cites] Eur J Clin Nutr. 1999 Oct;53(10):824-9 [10556991.001]
  • [Cites] Osteoporos Int. 2005 Mar;16 Suppl 2:S3-7 [15365697.001]
  • [Cites] Am J Clin Nutr. 2004 Dec;80(6):1645-9 [15585781.001]
  • [Cites] Osteoporos Int. 1999;9(1):45-54 [10367029.001]
  • [Cites] Am J Epidemiol. 2002 Apr 1;155(7):614-21 [11914188.001]
  • [Cites] BMJ. 2003 Aug 9;327(7410):316 [12907484.001]
  • [Cites] Am J Clin Nutr. 1987 Dec;46(6):1005-10 [3687818.001]
  • (PMID = 17211531.001).
  • [ISSN] 0937-941X
  • [Journal-full-title] Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
  • [ISO-abbreviation] Osteoporos Int
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


17. Fekecs T, Kádár Z, Battyáni Z, Kalmár-Nagy K, Szakály P, Horváth OP, Wéber G, Ferencz A: Incidence of nonmelanoma skin cancer after human organ transplantation: single-center experience in Hungary. Transplant Proc; 2010 Jul-Aug;42(6):2333-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of nonmelanoma skin cancer after human organ transplantation: single-center experience in Hungary.
  • There is increasing evidence that nonmelanoma skin cancers (NMSCs) are the most frequently observed tumors in transplant recipients.
  • All patients underwent a full skin examination for NMSC, and completed a standardized questionnaire.
  • Histologic analysis verified 13 basal cell carcinomas and 3 squamous cell carcinomas (ratio, 4:1).
  • These data indicate the relevance of skin cancer surveillance in transplant recipients.
  • Our results correspond to international statistics except for the ratio of basal cell carcinoma to squamous cell carcinoma.
  • [MeSH-major] Organ Transplantation / adverse effects. Skin Neoplasms / epidemiology
  • [MeSH-minor] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Female. Follow-Up Studies. Humans. Hungary / epidemiology. Kidney Transplantation / adverse effects. Male. Middle Aged. Pancreas Transplantation / adverse effects. Skin / pathology. Surveys and Questionnaires. Time Factors

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20692474.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Marcet S: Atypical fibroxanthoma/malignant fibrous histiocytoma. Dermatol Ther; 2008 Nov-Dec;21(6):424-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical fibroxanthoma/malignant fibrous histiocytoma.
  • Atypical fibroxanthoma (AFX) is an unusual spindle cell tumor occurring on actinically damaged skin of the head and neck.
  • Clinically, it is often confused with basal cell carcinoma, squamous cell carcinoma, or even melanoma.
  • Although initially thought to be a diagnosis of exclusion histologically, newer immunostains have helped in the identification of AFX.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Histiocytoma, Malignant Fibrous / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Humans. Mohs Surgery. Neoplasm Recurrence, Local


19. Johansen P, Berg K, Selbo PK, Hofbauer GF: [Photochemical internalisation (PCI): a further development of photodynamic therapy for the treatment of skin cancer]. Praxis (Bern 1994); 2010 Nov 17;99(23):1423-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Photochemical internalisation (PCI): a further development of photodynamic therapy for the treatment of skin cancer].
  • [Transliterated title] Photochemische Internalisierung (PCI): eine Weiterentwicklung der photodynamischen Therapie zur Behandlung von Hautkrebs.
  • Recently, several new and non-invasive methods have been introduced for the treatment of skin cancers.
  • Topical creams using the immune modulator imiquimod or the COX inhibitor diclofenac (with hyaluronic acid) are now registered for use against neoplasms such as basal or squamous cell carcinoma.
  • A refined version of PDT, namely photochemical internalisation, is currently subject to a first clinical trial in patients with osteosarcoma, squamous cell carcinoma, head and neck cancer as well as adenocarcinoma of the breast.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Melanoma / drug therapy. Photochemotherapy / methods. Skin Neoplasms / drug therapy
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacokinetics. Antineoplastic Agents / therapeutic use. Cytosol / drug effects. Endocytosis. Endosomes / drug effects. Humans. Melanoma, Experimental / drug therapy. Mice. Neoplasm Transplantation


20. Szeimies RM, Karrer S, Bäcker H: [Therapeutic options for epithelial skin tumors. Actinic keratoses, Bowen disease, squamous cell carcinoma, and basal cell carcinoma]. Hautarzt; 2005 May;56(5):430-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic options for epithelial skin tumors. Actinic keratoses, Bowen disease, squamous cell carcinoma, and basal cell carcinoma].
  • [Transliterated title] Therapieoptionen bei epithelialen Hauttumoren Aktinische Keratosen, Morbus Bowen, spinozelluläres Karzinom und Basalzellkarzinom.
  • There has been worldwide a significant rise in the incidence of epithelial skin tumors and their precursors in the past years with an increased number of younger patients affected.
  • In the following article different therapeutic approaches for actinic keratoses, Bowen's disease, basal cell carcinoma and squamous cell carcinoma are presented and analysed.
  • [MeSH-major] Risk Assessment / methods. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Bowen's Disease / diagnosis. Bowen's Disease / therapy. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Cryotherapy / methods. Curettage / methods. Humans. Keratosis / diagnosis. Keratosis / therapy. Practice Guidelines as Topic. Practice Patterns, Physicians'. Risk Factors

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Strahlenther Onkol. 2001 May;177(5):240-6 [11398609.001]
  • [Cites] Br J Dermatol. 2001 Mar;144(3):567-74 [11260016.001]
  • [Cites] Int J Dermatol. 2001 Nov;40(11):709-13 [11737438.001]
  • [Cites] J Am Acad Dermatol. 2001 Mar;44(3):462-70 [11209116.001]
  • [Cites] J Am Acad Dermatol. 1999 Sep;41(3 Pt 1):414-8 [10459115.001]
  • [Cites] Dermatologica. 1979;158(5):368-72 [437226.001]
  • [Cites] Int J Dermatol. 2004 Sep;43(9):687-92 [15357755.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):722-33 [15097956.001]
  • [Cites] Clin Exp Dermatol. 1999 Jul;24(4):338-9 [10457144.001]
  • [Cites] J Dermatol Surg Oncol. 1989 Apr;15(4):424-31 [2925988.001]
  • [Cites] J Am Acad Dermatol. 2002 Aug;47(2):258-62 [12140473.001]
  • [Cites] J Am Acad Dermatol. 1982 Nov;7(5):631-2 [7142470.001]
  • [Cites] J Drugs Dermatol. 2004 Jul-Aug;3(4):401-7 [15303784.001]
  • [Cites] Dermatol Surg. 2004 Sep;30(9):1214-8 [15355363.001]
  • [Cites] Br J Dermatol. 1999 Oct;141(4):633-41 [10583109.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2003 Mar;17(2):167-70 [12705745.001]
  • [Cites] Dermatol Surg. 2000 Aug;26(8):759-64 [10940063.001]
  • [Cites] Br J Dermatol. 2000 Apr;142(4):752-7 [10792227.001]
  • [Cites] Br J Dermatol. 2003 Nov;149 Suppl 66:43-9 [14616349.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):148-56 [15270884.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):555-9 [10225444.001]
  • [Cites] Arch Dermatol. 2002 Nov;138(11):1498-502 [12437457.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 1):517-20 [15056141.001]
  • [Cites] Eur J Dermatol. 2002 Nov-Dec;12(6):558-61 [12459527.001]
  • [Cites] J Am Acad Dermatol. 1998 Mar;38(3):438-42 [9520026.001]
  • [Cites] Australas J Dermatol. 2000 Feb;41(1):19-30 [10715896.001]
  • [Cites] J Am Acad Dermatol. 2004 Oct;51(4):547-55 [15389189.001]
  • [Cites] Clin Dermatol. 2001 May-Jun;19(3):328-38 [11479045.001]
  • [Cites] Arch Dermatol. 2004 Oct;140(10 ):1284-5 [15492200.001]
  • [Cites] J Dermatolog Treat. 2003 Jun;14(2):99-106 [12775317.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):141-7 [15270883.001]
  • [Cites] Br J Cancer. 1997;76(1):100-6 [9218740.001]
  • [Cites] Br J Dermatol. 2001 Apr;144(4):832-40 [11298545.001]
  • [Cites] Arch Dermatol. 2004 Oct;140(10 ):1286-7 [15492202.001]
  • [Cites] Br J Dermatol. 2003 Mar;148(3):539-43 [12653747.001]
  • [Cites] J Am Acad Dermatol. 1997 Jan;36(1):72-7 [8996264.001]
  • [Cites] Dermatol Surg. 2003 Nov;29(11):1150-3; discussion 1153 [14641346.001]
  • [Cites] Dermatol Surg. 2001 Feb;27(2):143-6 [11207687.001]
  • [Cites] J Am Acad Dermatol. 2003 Sep;49(3):483-6 [12963913.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1766-72 [15541449.001]
  • [Cites] Br J Dermatol. 1996 Nov;135(5):766-71 [8977678.001]
  • [Cites] J Dermatol Surg Oncol. 1991 Sep;17(9):720-6 [1820764.001]
  • [Cites] Clin Radiol. 1986 Jan;37(1):33-4 [3514075.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):714-21 [15097955.001]
  • [Cites] Clin Ther. 2002 Jun;24(6):990-1000 [12117087.001]
  • [Cites] Lasers Surg Med. 2004;34(2):114-9 [15004822.001]
  • (PMID = 15815888.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 48
  •  go-up   go-down


21. Moan J, Porojnicu AC, Dahlback A: Ultraviolet radiation and malignant melanoma. Adv Exp Med Biol; 2008;624:104-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultraviolet radiation and malignant melanoma.
  • Essential features of the epidemiology and photobiology of cutaneous malignant melanoma (CMM) in Norway were studied in comparison with data from countries at lower latitudes.
  • This hypothesis was supported both by latitude gradients, by time trends and by changing patterns of tumor density on different body localizations.
  • Comparisons of skin cancer data from Norway and Australia/New Zealand indicate that squamous cell carcinoma and basal cell carcinoma are mainly related to annual solar UVB fluences, while UVA fluences play a larger role for CMM.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Melanoma / epidemiology. Skin Neoplasms / epidemiology. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18348451.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 52
  •  go-up   go-down


22. Abdel-Malek ZA, Kadekaro AL, Swope VB: Stepping up melanocytes to the challenge of UV exposure. Pigment Cell Melanoma Res; 2010 Apr;23(2):171-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Exposure to solar ultraviolet radiation (UV) is the main etiological factor for skin cancer, including melanoma.
  • Therefore, maintaining genomic stability of melanocytes is crucial for prevention of melanoma, as well as keratinocyte-derived basal and squamous cell carcinoma.
  • The response of melanocytes to UV is mediated mainly by a network of paracrine factors that not only activate melanogenesis, but also DNA repair, anti-oxidant, and survival pathways that are pivotal for maintenance of genomic stability and prevention of malignant transformation or apoptosis.
  • Unraveling these mechanisms might lead to strategies to prevent melanoma, as well as non-melanoma skin cancer.
  • [MeSH-major] DNA Repair / physiology. Genomic Instability. Melanocytes / metabolism. Melanoma / metabolism. Skin Neoplasms / metabolism. Ultraviolet Rays

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pigment Cell Melanoma Res. 2011 Apr;24(2):265-7 [21513010.001]
  • (PMID = 20128873.001).
  • [ISSN] 1755-148X
  • [Journal-full-title] Pigment cell & melanoma research
  • [ISO-abbreviation] Pigment Cell Melanoma Res
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / P30-ES006096; United States / NCI NIH HHS / CA / R01CA114095; United States / NIEHS NIH HHS / ES / R01ES009110; United States / NIEHS NIH HHS / ES / R01ES017561
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Number-of-references] 197
  •  go-up   go-down


23. Fabbrocini G, Triassi M, Mauriello MC, Torre G, Annunziata MC, De Vita V, Pastore F, D'Arco V, Monfrecola G: Epidemiology of skin cancer: role of some environmental factors. Cancers (Basel); 2010;2(4):1980-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of skin cancer: role of some environmental factors.
  • The incidence rate of melanoma and non-melanoma skin cancer entities is dramatically increasing worldwide.
  • Exposure to UVB radiation is known to induce basal and squamous cell skin cancer in a dose-dependent way and the depletion of stratospheric ozone has implications for increases in biologically damaging solar UVB radiation reaching the earth's surface.
  • In humans, arsenic is known to cause cancer of the skin, as well as cancer of the lung, bladder, liver, and kidney.
  • SCC and BCC (squamous and basal cell carcinoma) have been reported to be associated with ingestion of arsenic alone or in combination with other risk factors.
  • Higher temperatures accompanying climate change may lead, among many other effects, to increasing incidence of skin cancer.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24281212.001).
  • [ISSN] 2072-6694
  • [Journal-full-title] Cancers
  • [ISO-abbreviation] Cancers (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ PMC3840456
  •  go-up   go-down


2
Advertisement
4. Mogensen M, Jemec GB: Diagnosis of nonmelanoma skin cancer/keratinocyte carcinoma: a review of diagnostic accuracy of nonmelanoma skin cancer diagnostic tests and technologies. Dermatol Surg; 2007 Oct;33(10):1158-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of nonmelanoma skin cancer/keratinocyte carcinoma: a review of diagnostic accuracy of nonmelanoma skin cancer diagnostic tests and technologies.
  • BACKGROUND: Nonmelanoma skin cancer (NMSC) is the most prevalent cancer in the light-skinned population.
  • OBJECTIVE: The scope of this review is to present data on the current state-of-the-art diagnostic methods for keratinocyte carcinoma: basal cell carcinoma, squamous cell carcinoma, and actinic keratosis.
  • [MeSH-major] Skin Neoplasms / diagnosis
  • [MeSH-minor] Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / ultrasonography. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / ultrasonography. Dermoscopy. Diagnostic Tests, Routine. Humans. Keratosis / diagnosis. Keratosis / pathology. Keratosis / ultrasonography

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17903149.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 128
  •  go-up   go-down


25. Bouwes Bavinck JN, Euvrard S, Naldi L, Nindl I, Proby CM, Neale R, Abeni D, Tessari GP, Feltkamp MC, Claudy A, Stockfleth E, Harwood CA, EPI-HPV-UV-CA group: Keratotic skin lesions and other risk factors are associated with skin cancer in organ-transplant recipients: a case-control study in The Netherlands, United Kingdom, Germany, France, and Italy. J Invest Dermatol; 2007 Jul;127(7):1647-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Keratotic skin lesions and other risk factors are associated with skin cancer in organ-transplant recipients: a case-control study in The Netherlands, United Kingdom, Germany, France, and Italy.
  • This study examines the association of keratotic skin lesions with the development of skin cancer in 915 solid organ-transplant recipients in five European countries.
  • In a hospital-based case-control study, cases with squamous- and basal-cell carcinoma were compared with controls without skin cancer.
  • Questionnaires, scrutiny of medical charts, and skin examination were delivered according to a standardized protocol.
  • Keratotic skin lesions and viral warts were counted on different body sites.
  • Keratotic skin lesions were strongly associated with an increased risk of squamous-cell carcinoma, with adjusted odds ratios of 4.1 (2.4;7.0) and 12.1 (6.1;24) for 1-49 and 50 and more keratotic skin lesions compared with no lesions, respectively.
  • Keratotic skin lesions were also associated with basal-cell carcinoma with adjusted odds ratios of 2.9 (1.7;4.9) and 4.0 (1.7;9.2) for 1-49 and 50 and more lesions, respectively.
  • Lighter skin types and painful sunburns were also significantly associated with an increased risk of squamous- and basal-cell carcinoma.
  • Keratotic skin lesions are strongly associated with skin cancer and are, thus, an important clinical criterion for identifying those organ-transplant recipients at an increased risk of skin cancers who should be offered more intensive skin surveillance.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Keratosis / epidemiology. Keratosis / pathology. Skin Neoplasms / etiology. Transplantation / adverse effects
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Europe / epidemiology. Female. Humans. Life Style. Male. Middle Aged. Papillomavirus Infections / epidemiology. Risk Factors. Sex Characteristics. Skin Pigmentation. Sunlight / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Rev Oncol Hematol. 2005 Oct;56(1):87-99 [15979889.001]
  • [Cites] J Am Acad Dermatol. 2000 Feb;42(2 Pt 1):307 [10642700.001]
  • [Cites] Transplantation. 2000 Jan 15;69(1):44-9 [10653378.001]
  • [Cites] J Clin Microbiol. 2000 Jun;38(6):2087-96 [10834958.001]
  • [Cites] J Med Virol. 2000 Jul;61(3):289-97 [10861635.001]
  • [Cites] Am J Kidney Dis. 2000 Jul;36(1):167-76 [10873887.001]
  • [Cites] Br J Dermatol. 2000 Sep;143(3):513-9 [10971322.001]
  • [Cites] Genes Dev. 2000 Dec 1;14(23):3065-73 [11114894.001]
  • [Cites] Transplantation. 2000 Nov 27;70(10):1479-84 [11118094.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):231-8 [11134217.001]
  • [Cites] J Photochem Photobiol B. 2001 Oct;63(1-3):8-18 [11684447.001]
  • [Cites] J Am Acad Dermatol. 2002 Jul;47(1):1-17; quiz 18-20 [12077575.001]
  • [Cites] EMBO J. 2002 Sep 2;21(17):4741-8 [12198176.001]
  • [Cites] Br J Dermatol. 2002 Nov;147(5):950-6 [12410706.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1681-91 [12711744.001]
  • [Cites] Acta Otolaryngol. 2005 Sep;125(9):991-8 [16193590.001]
  • [Cites] Acta Derm Venereol. 2003;83(3):189-93 [12816154.001]
  • [Cites] Arch Dermatol. 2003 Jul;139(7):890-4 [12873884.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1221-7 [14520450.001]
  • [Cites] Arch Dermatol Res. 2003 Dec;295(7):273-9 [14618345.001]
  • [Cites] J Invest Dermatol. 2003 Dec;121(6):1531-5 [14675206.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1540-3 [14693751.001]
  • [Cites] N Engl J Med. 2004 Jun 24;350(26):2639-42 [15215478.001]
  • [Cites] Science. 2005 Sep 16;309(5742):1871-4 [16166520.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2695-700 [12750299.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 15;98(6):389-95 [16537831.001]
  • [Cites] Br J Dermatol. 2006 Mar;154(3):498-504 [16445782.001]
  • [Cites] Arch Dermatol. 2004 Sep;140(9):1079-85 [15381547.001]
  • [Cites] J Invest Dermatol. 2005 Jul;125(1):93-7 [15982308.001]
  • [Cites] J Clin Microbiol. 1999 Nov;37(11):3545-55 [10523550.001]
  • [Cites] Transplantation. 1996 Mar 15;61(5):715-21 [8607173.001]
  • [Cites] J Invest Dermatol. 1995 Sep;105(3):367-71 [7665914.001]
  • [Cites] Br J Dermatol. 1993 Sep;129(3):242-9 [8286220.001]
  • [Cites] N Engl J Med. 1991 Sep 19;325(12):843-8 [1875968.001]
  • [Cites] Acta Derm Venereol. 1990;70(6):491-4 [1981421.001]
  • [Cites] Transplantation. 1990 Mar;49(3):506-9 [2316011.001]
  • [Cites] Q J Med. 1987 Jul;64(243):609-16 [3313494.001]
  • [Cites] Lancet. 1984 Mar 31;1(8379):702-5 [6143041.001]
  • (PMID = 17380113.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A6695
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2478722; NLM/ UKMS1916
  •  go-up   go-down


26. Wagoner J, Keehn C, Morgan MB: CD-10 immunostaining differentiates superficial basal cell carcinoma from cutaneous squamous cell carcinoma. Am J Dermatopathol; 2007 Dec;29(6):555-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD-10 immunostaining differentiates superficial basal cell carcinoma from cutaneous squamous cell carcinoma.
  • Basal cell carcinoma and squamous cell carcinoma are common entities in clinical practice.
  • We sought to determine if the CD10 immunostain could have diagnostic utility in distinguishing between early superficial basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
  • CD10 was negative in the tumor cells in 13 out of 13 superficially invasive SCCs and SCC in situ.
  • These findings support the utility of CD10 as a marker for early BCC, especially when SCC cannot be excluded clinically or by conventional stains.
  • Furthermore, these results implicate CD10 in the pathogenesis of BCC.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma in Situ / diagnosis. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Neprilysin / analysis. Skin Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18032951.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


27. Leiter U, Garbe C: [Skin cancer in organ transplant patients. Epidemiology and management]. Hautarzt; 2010 Mar;61(3):207-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Skin cancer in organ transplant patients. Epidemiology and management].
  • Skin cancer is the most common cancer, representing 40-50% of post transplant malignancies.
  • In the first 10 years post transplantation, some 15%-40% of patients develop skin cancer, primarily squamous cell carcinoma and basal cell carcinoma, but also melanoma, Merkel cell carcinoma and virally-induced Kaposi sarcoma.
  • The management of skin cancer includes secondary prophylaxis and address attention to areas of widespread actinic damage, usually with topical agents.
  • In high risk skin cancer or metastatic disease a substantial reduction in immunosuppression to switching to mTOR inhibitors appears to substantially improve the prognosis.
  • The management of the individual tumor types is discussed; in general it follows the current guidelines.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Immunosuppressive Agents / administration & dosage. Organ Transplantation / statistics & numerical data. Postoperative Complications / epidemiology. Postoperative Complications / prevention & control. Skin Neoplasms / epidemiology. Skin Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Melanoma Res. 2008 Apr;18(2):152-60 [18337653.001]
  • [Cites] J Dtsch Dermatol Ges. 2008 May;6 Suppl 1:S15-6 [18801136.001]
  • [Cites] Am J Transplant. 2008 Sep;8(9):1891-900 [18786232.001]
  • [Cites] Curr Opin Oncol. 2009 May;21(3):232-7 [19370807.001]
  • [Cites] Transplantation. 1999 Dec 15;68(11):1717-21 [10609948.001]
  • [Cites] J Am Acad Dermatol. 2000 Feb;42(2 Pt 1):307 [10642700.001]
  • [Cites] Br J Dermatol. 2000 Sep;143(3):513-9 [10971322.001]
  • [Cites] J Dtsch Dermatol Ges. 2008 May;6 Suppl 1:S2-4 [18801139.001]
  • [Cites] ScientificWorldJournal. 2008 Sep 21;8:909-19 [18836658.001]
  • [Cites] Br J Dermatol. 2007 May;156 Suppl 3:40-2 [17488405.001]
  • [Cites] J Am Acad Dermatol. 2005 Nov;53(5):783-90 [16243126.001]
  • [Cites] Am J Transplant. 2006 Sep;6(9):2164-8 [16780549.001]
  • [Cites] Transplantation. 2009 Aug 27;88(4):597-8 [19696647.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):1-12 [17520670.001]
  • [Cites] Dermatol Surg. 2009 Oct;35(10):1567-72 [19681993.001]
  • [Cites] Am J Transplant. 2008 Nov;8(11):2192-8 [18782290.001]
  • [Cites] Dermatol Surg. 2002 Feb;28(2):113-7; discussion 117 [11860419.001]
  • [Cites] J Invest Dermatol. 2006 Mar;126(3):569-74 [16374480.001]
  • [Cites] Transplantation. 2006 Dec 27;82(12):1792-3 [17198278.001]
  • [Cites] Br J Dermatol. 2008 Jul;159(1):35-48 [18593385.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1681-91 [12711744.001]
  • [Cites] Am J Transplant. 2004 Jun;4(6):905-13 [15147424.001]
  • [Cites] J Dtsch Dermatol Ges. 2008 May;6 Suppl 1:S19-24 [18801138.001]
  • [Cites] J Dtsch Dermatol Ges. 2008 May;6 Suppl 1:S9-S14 [18801142.001]
  • [Cites] J Dtsch Dermatol Ges. 2008 May;6 Suppl 1:S5-8 [18801141.001]
  • [Cites] Transplantation. 1990 Mar;49(3):506-9 [2316011.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Sep;5(9):510-1 [18679393.001]
  • [Cites] J Am Acad Dermatol. 2008 Sep;59(3):405-17 [18556089.001]
  • [Cites] Transplant Proc. 1988 Jun;20(3 Suppl 3):885-92 [3388524.001]
  • [Cites] Melanoma Res. 2008 Feb;18(1):61-7 [18227710.001]
  • [Cites] Swiss Med Wkly. 2009 Jul 25;139(29-30):407-15 [19680830.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):642-50 [15061849.001]
  • [Cites] J Am Acad Dermatol. 2002 Jul;47(1):1-17; quiz 18-20 [12077575.001]
  • [Cites] Transplantation. 1997 Sep 15;64(5):669-73 [9311700.001]
  • [Cites] J Clin Microbiol. 2001 Feb;39(2):506-8 [11158097.001]
  • [Cites] Br J Dermatol. 2006 Aug;155(2):451-4 [16882188.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2659-65 [16763280.001]
  • [Cites] Transplantation. 2004 Feb 27;77(4):574-9 [15084938.001]
  • [Cites] Br J Dermatol. 2007 Dec;157 Suppl 2:25-31 [18067628.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):622-7 [15061846.001]
  • [Cites] Transplantation. 1996 Mar 15;61(5):715-21 [8607173.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Jun;19(5):365-6 [17379490.001]
  • [Cites] Br J Dermatol. 2007 Dec;157(6):1183-8 [17916206.001]
  • [Cites] Arch Dermatol. 2001 Apr;137(4):459-63 [11295926.001]
  • (PMID = 20145902.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents
  •  go-up   go-down


28. Kummoona R: Periorbital and orbital malignancies: methods of management and reconstruction in Iraq. J Craniofac Surg; 2007 Nov;18(6):1370-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor types were squamous cell carcinoma, basal cell carcinoma, conjunctival squamous cell carcinoma, retinoblastoma, fibrosarcoma, and ectopic mixed tumor in two, one, two, one, one, and one patients, respectively, in addition to eight patients with jaw lymphoma involving the orbit, out of 24 patients reported by us.
  • Surgery consisted of complete excision of orbital content (exenteration) with or without partial orbitectomy in four patients and wide excision of the tumor in four patients.
  • Reconstruction of the defect was accomplished using various local skin flaps and temporalis muscle flap was used for augmenting the orbit in the four exenterated patients.
  • There is no single best method for reconstruction of the periorbital and orbital defects left after tumor resection, and different flaps applied for reconstruction had given satisfactory results related to the type and complexity of the deformity.
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Child. Child, Preschool. Eye Enucleation. Female. Humans. Infant. Iraq. Lymphoma / chemistry. Lymphoma / surgery. Male. Middle Aged. Radiotherapy, Adjuvant. Skin Transplantation

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17993883.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Rodríguez-Domínguez FJ, Hernández-Gil J, Segarra Fenoll JD, Hernández-Gil A: [Facial mutilant basosquamous carcinoma]. An Otorrinolaringol Ibero Am; 2007;34(6):549-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Facial mutilant basosquamous carcinoma].
  • [Transliterated title] Carcinoma basoescamoso mutilante en región facial.
  • Basosquamous carcinoma is a rare epithelial malignant neoplasm with clinical and biological features of both basal and squamous cell carcinoma.
  • This neoplasm has been characterized for years as a variant of basal cell carcinoma, although now it is widely accepted as a clinical entity.
  • The most important features of basosquamous carcinoma are its great local aggressiveness, high frequency of recurrences and its metastatic potential.
  • [MeSH-major] Carcinoma, Basosquamous / pathology. Head and Neck Neoplasms / pathology. Palliative Care / methods
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Face. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18293774.001).
  • [ISSN] 0303-8874
  • [Journal-full-title] Anales otorrinolaringológicos ibero-americanos
  • [ISO-abbreviation] An Otorrinolaringol Ibero Am
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


30. Tichý M, Ditrichová D, Brychtová S, Tichá V, Urbánek J: Double skin tumors with an atypical clinical picture. Acta Dermatovenerol Alp Pannonica Adriat; 2007 Jun;16(2):63-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Double skin tumors with an atypical clinical picture.
  • The authors present a rare case of double skin tumors: acral lentiginous melanoma and metatypical carcinoma.
  • The skin biopsies showed advanced acral lentiginous melanoma on the sole and metatypical carcinoma of the lower leg.
  • Soon after the diagnosis was made, the melanoma generalized.
  • The article discusses the differential diagnosis of both leg ulcerations, correct diagnostic procedures, and characteristic features of both tumors that are important questions for general practitioners, dermatologists, and surgeons.
  • [MeSH-major] Carcinoma / diagnosis. Leg Ulcer / etiology. Melanoma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Foot Ulcer / etiology. Humans. Male

  • MedlinePlus Health Information. consumer health - Leg Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17992460.001).
  • [ISSN] 1318-4458
  • [Journal-full-title] Acta dermatovenerologica Alpina, Pannonica, et Adriatica
  • [ISO-abbreviation] Acta Dermatovenerol Alp Pannonica Adriat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Slovenia
  •  go-up   go-down


31. Kolm I, Hofbauer G, Braun RP: [Early diagnosis of skin cancer]. Ther Umsch; 2010 Sep;67(9):439-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Early diagnosis of skin cancer].
  • The skin is the most affected organ by cancer.
  • The incidence rates of skin cancer are steadily increasing, both for melanoma and non-melanoma skin cancers (squamous cell carcinoma, basal cell carcinoma).
  • Over 90 % of the death cases from skin cancers attribute to melanoma.
  • In the last years a number of new non invasive techniques for the early diagnosis of melanoma have been developed which are superior to the naked eye examination.
  • In this overview article we present some non-invasive diagnostic techniques like total body photography, digital dermoscopy and confocal microscopy which in addition to dermoscopy assist the dermatologist in differentiating nevi from early melanomas.Non-melanoma skin cancer can be prevented by accurate sun protection.
  • Early squamous cell carcinomas and basal cell carcinomas can be treated either invasively or non-invasively with excellent prognosis.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / prevention & control. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / prevention & control. Melanoma / diagnosis. Melanoma / prevention & control. Precancerous Conditions / diagnosis. Precancerous Conditions / prevention & control. Skin Neoplasms / diagnosis. Skin Neoplasms / prevention & control
  • [MeSH-minor] Dermoscopy. Early Diagnosis. Humans. Microscopy, Confocal. Photography. Risk Factors. Skin / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20806172.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  •  go-up   go-down


32. Dixon A, Rosengren H, Connelly T, Dixon J: Education in skin cancer management--assessing knowledge and safety. Aust Fam Physician; 2009 Jul;38(7):557-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Education in skin cancer management--assessing knowledge and safety.
  • BACKGROUND: General practitioners manage the majority of skin cancers in Australia.
  • There are a range of training opportunities for, and certifications in, skin cancer management.
  • METHOD: Between 15 June and 25 June 2008, an online examination was placed on the Australasian College of Skin Cancer Medicine website.
  • Thirty questions were asked pertaining to the management of a hypothetical case study including melanoma, basal cell carcinoma and squamous cell carcinoma.
  • Two days of training may not make doctors sufficiently safe in skin cancer management; it appeared to improved knowledge, but not to a point where unsafe practice was eliminated.
  • [MeSH-major] Family Practice / education. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575076.001).
  • [ISSN] 0300-8495
  • [Journal-full-title] Australian family physician
  • [ISO-abbreviation] Aust Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


33. Hoang MP, Dresser KA, Kapur P, High WA, Mahalingam M: Microcystic adnexal carcinoma: an immunohistochemical reappraisal. Mod Pathol; 2008 Feb;21(2):178-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microcystic adnexal carcinoma: an immunohistochemical reappraisal.
  • Even though immunohistochemical comparisons of microcystic adnexal carcinoma vs infiltrative basal cell carcinoma and desmoplastic trichoepithelioma exist, they are mostly restricted to the use of a single stain.
  • In addition, a comparison with squamous cell carcinoma has not been reported previously.
  • In this study, we compare the expression of cytokeratin (CK) 15, CK7, CK20, CK903, carcinoembryonic antigen (CEA), CD10, CD15 and BerEP4 in 13 microcystic adnexal carcinoma, eight desmoplastic trichoepithelioma, 10 infiltrative basal cell carcinoma, and eight squamous cell carcinoma of which five exhibited ductal differentiation.
  • We found that the majority of microcystic adnexal carcinoma (92%) and desmoplastic trichoepithelioma (100%) cases expressed CK15 while the infiltrative basal cell carcinoma and squamous cell carcinoma cases were all negative.
  • Forty percent of infiltrative basal cell carcinoma expressed CK7; while only two microcystic adnexal carcinoma cases (15%) and one squamous cell carcinoma with ductal differentiation (12%) expressed CK7 in the remaining three tumor categories.
  • While the neoplastic cells were negative, luminal staining of ductal structures was noted for CK7, CD15 and CEA in some of the microcystic adnexal carcinoma, desmoplastic trichoepithelioma and squamous cell carcinoma with ductal differentiation cases.
  • Sixty percent of infiltrative basal cell carcinoma, 31% of microcystic adnexal carcinoma, and 25% of squamous cell carcinoma express CD10.
  • BerEP4 expression was noted in 38% of microcystic adnexal carcinoma, 57% of desmoplastic trichoepithelioma, 100% of infiltrative basal cell carcinoma, and 38% of squamous cell carcinoma.
  • In conclusion, we found CK15 to be a useful marker in distinguishing microcystic adnexal carcinoma from infiltrative basal cell carcinoma and squamous cell carcinoma with ductal differentiation.
  • Our experience indicates that microcystic adnexal carcinoma and desmoplastic trichoepithelioma have a similar immunohistochemical profile that is, CK15+ and BerEP4+/-; thus, additional studies are needed to separate these two entities.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Skin Appendage / chemistry. Head and Neck Neoplasms / chemistry. Immunohistochemistry / methods. Skin Neoplasms / chemistry
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / chemistry. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / chemistry. Carcinoma, Squamous Cell / diagnosis. Diagnosis, Differential. Female. Humans. Keratin-15 / analysis. Male. Middle Aged


34. Skroza N, Panetta C, Schwartz RA, Balzani A, Rota C, Buccheri EM, Alfano C, Innocenzi D: Giant meta-typical carcinoma: an unusual tumor. Acta Dermatovenerol Croat; 2006;14(1):46-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant meta-typical carcinoma: an unusual tumor.
  • Meta-typical carcinoma (MTC) or basosquamous carcinoma is a remarkable malignancy with features of both basal and squamous cell carcinoma.
  • It is typically located on the back and face, often with clinical features of basal cell carcinoma but tending to be more aggressive with enhanced prospects of lymph node or distant metastases.
  • Our report describes a huge neglected MTC of the back of ten-year duration, a giant ulcero-vegetative tumor measuring 20 x 25 cm.
  • Histologic examination of specimens from the margins and periphery revealed aspects of both basal and squamous cell carcinoma, while the ulcerated center showed sclerotic tissue without tumor.
  • This may have been related to an intense inflammatory host response with elimination of neoplastic tissue and consequent local sclerosis evident in the central tumor-free portion.
  • This central tumor regression is to our knowledge a unique finding in MTC.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16603102.001).
  • [ISSN] 1330-027X
  • [Journal-full-title] Acta dermatovenerologica Croatica : ADC
  • [ISO-abbreviation] Acta Dermatovenerol Croat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


35. Hönigsmann H, Diepgen TL: [UV-induced skin cancers]. J Dtsch Dermatol Ges; 2005 Sep;3 Suppl 2:S26-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [UV-induced skin cancers].
  • In this review the epidemiology and pathogenetic aspects of UV-induced malignant skin tumours (basal cell carcinoma, squamous cell carcinoma and melanoma) are discussed with regard to current literature.
  • Whereas present knowledge, in particular, gained from experimental data, permits substantial conclusions about the development of squamous cell carcinoma, the situation for basal cell carcinoma and melanoma does not appear to be unequivocally clear.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Carcinoma, Squamous Cell / etiology. Melanoma / etiology. Neoplasms, Radiation-Induced / etiology. Skin Neoplasms / etiology. Ultraviolet Rays / adverse effects
  • [MeSH-minor] Adolescent. Age Factors. Child. DNA Damage. DNA Repair. Humans. Risk Factors. Skin / pathology. Sunburn / complications

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16117740.001).
  • [ISSN] 1610-0379
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 37
  •  go-up   go-down


36. Lehnerdt G, Manz D, Jahnke K, Schmitz KJ: [Cutaneous basosquamous cell carcinoma]. HNO; 2008 Mar;56(3):306-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cutaneous basosquamous cell carcinoma].
  • [Transliterated title] Basosquamöses Karzinom der Haut.
  • BACKGROUND: Basosquamous carcinoma (BSC) is a rare malignancy with specific histopathological features of both basal cell (BCC) and squamous cell carcinoma (SCC).
  • Therefore, the histological diagnosis is challenging.
  • In the case of the carcinoma on the forehead, a local excision was performed.
  • CONCLUSIONS: The histological diagnosis of BSC is confirmed by the use of EMA and BerEP4 immunohistological staining.
  • Clinically, BSC is a rare, aggressive skin tumor.
  • Despite the histological similarity to basal cell carcinoma, BSC has an imminent risk of metastasizing.
  • [MeSH-major] Carcinoma, Basosquamous / pathology. Carcinoma, Basosquamous / surgery. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / surgery. Otorhinolaryngologic Surgical Procedures / methods. Skin Neoplasms / pathology. Skin Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Treatment Outcome


37. McKnight CA, Wise AG, Maes RK, Howe C, Rector A, Van Ranst M, Kiupel M: Papillomavirus-associated basosquamous carcinoma in an Egyptian fruit bat (Rousettus aegyptiacus). J Zoo Wildl Med; 2006 Jun;37(2):193-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillomavirus-associated basosquamous carcinoma in an Egyptian fruit bat (Rousettus aegyptiacus).
  • Six additional variably sized, raised, smooth to cauliflower-like skin masses were observed randomly distributed throughout the left wing membranes.
  • Four masses were removed and diagnosed microscopically as basosquamous carcinomas and papillomas.
  • Additional masses, removed 6 mo and 1 yr later, showed bony invasion and squamous differentiation.
  • Polymerase chain reaction done on DNA extracts from formalin-fixed, paraffin-embedded tumor tissue amplified a 450 base-pair segment analogous to the L1 region of human papillomavirus types 96 and 5.
  • To our knowledge, this is the first report of papillomavirus-associated carcinoma in a chiropteran species.
  • [MeSH-major] Carcinoma, Squamous Cell / veterinary. Chiroptera / virology. Papillomaviridae / isolation & purification. Papillomavirus Infections / veterinary. Skin Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17312801.001).
  • [ISSN] 1042-7260
  • [Journal-full-title] Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
  • [ISO-abbreviation] J. Zoo Wildl. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


38. Tarallo M, Cigna E, Frati R, Delfino S, Innocenzi D, Fama U, Corbianco A, Scuderi N: Metatypical basal cell carcinoma: a clinical review. J Exp Clin Cancer Res; 2008;27:65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metatypical basal cell carcinoma: a clinical review.
  • BACKGROUND: Metatypical cell carcinoma can be considered as a new entity of skin cancer, being an intermediate typology between basal cell carcinomas and squamous cell carcinomas.
  • The behaviour of the metatypical cell carcinoma lies between these two varieties of skin cancer.
  • It is difficult to perform a differential diagnosis based on morphological and clinical features - therefore it is only possible by accurate histology.
  • METHODS: The authors have retrospectively analysed clinical records of 240 patients who were affected by metatypical skin cancer and who were treated by surgery, radiotherapy and chemotherapy.
  • CONCLUSION: In this manuscript, the authors have emphasised the importance of conducting a differential diagnosis, and the importance of the specific treatment for metatypical skin cancer, even though more clinical studies and long-term follow-ups are required before establishing specific guidelines.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for metatypical basal cell carcinoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 2001 Feb;44(2):224-30 [11174379.001]
  • [Cites] Plast Reconstr Surg. 2001 Apr 1;107(4):942-7 [11252086.001]
  • [Cites] Plast Reconstr Surg. 2002 Apr 1;109(4):1466-7 [11965016.001]
  • [Cites] Br J Dermatol. 2002 Apr;146 Suppl 61:1-6 [11966724.001]
  • [Cites] Virchows Arch. 2002 Dec;441(6):551-8 [12461611.001]
  • [Cites] Otolaryngol Head Neck Surg. 2003 May;128(5):663-73 [12748559.001]
  • [Cites] Dermatol Surg. 2003 Jul;29(7):700-11 [12828693.001]
  • [Cites] Dermatol Surg. 2003 Aug;29(8):830-2; discussion 833 [12859383.001]
  • [Cites] J Craniomaxillofac Surg. 2004 Feb;32(1):16-8 [14729044.001]
  • [Cites] Dermatol Surg. 2004 Feb;30(2 Pt 2):248-52 [14871217.001]
  • [Cites] Br J Ophthalmol. 2004 Mar;88(3):358-60 [14977769.001]
  • [Cites] Acta Derm Venereol. 2004;84(1):44-7 [15040477.001]
  • [Cites] Arch Facial Plast Surg. 2004 May-Jun;6(3):158-61 [15148122.001]
  • [Cites] Br J Oral Maxillofac Surg. 2004 Aug;42(4):311-4 [15225948.001]
  • [Cites] Arch Dermatol. 1965 Dec;92(6):635-7 [5846318.001]
  • [Cites] Br J Dermatol. 1973 Jul;89(1):37-43 [4788317.001]
  • [Cites] Ophthalmologica. 1983;187(1):51-8 [6877760.001]
  • [Cites] Arkh Patol. 1983;45(6):35-9 [6625927.001]
  • [Cites] J Am Acad Dermatol. 1984 Oct;11(4 Pt 1):557-62 [6490979.001]
  • [Cites] Dermatologica. 1985;171(1):21-6 [2411609.001]
  • [Cites] Arch Dermatol. 1987 Mar;123(3):340-4 [3813602.001]
  • [Cites] J Dermatol Surg Oncol. 1987 May;13(5):556-7 [3571694.001]
  • [Cites] J Dermatol Surg Oncol. 1988 Jun;14(6):600-2 [3372843.001]
  • [Cites] Dermatol Clin. 1988 Jul;6(3):397-405 [3048822.001]
  • [Cites] Mod Pathol. 1991 May;4(3):325-30 [2068058.001]
  • [Cites] J Am Acad Dermatol. 1992 Jan;26(1):1-26 [1732313.001]
  • [Cites] Pathol Res Pract. 1991 Dec;187(8):978-85 [1792194.001]
  • [Cites] J Am Acad Dermatol. 1992 Jun;26(6):976-90 [1607418.001]
  • [Cites] J Am Acad Dermatol. 1992 Aug;27(2 Pt 1):241-8 [1430364.001]
  • [Cites] J Invest Dermatol. 1994 Jun;102(6):6S-9S [8006441.001]
  • [Cites] Cancer. 1995 Jan 15;75(2 Suppl):667-73 [7804993.001]
  • [Cites] Arkh Patol. 1994 Jul-Aug;56(4):35-8 [7848103.001]
  • [Cites] Ann Chir Plast Esthet. 1994 Apr;39(2):176-83 [7872634.001]
  • [Cites] Am J Surg. 1995 Nov;170(5):446-50 [7485729.001]
  • [Cites] Laryngoscope. 1996 Feb;106(2 Pt 1):156-8 [8583845.001]
  • [Cites] Am J Dermatopathol. 1996 Feb;18(1):35-42 [8721589.001]
  • [Cites] Neurosurgery. 1997 Jul;41(1):279-81; discussion 281-2 [9218319.001]
  • [Cites] J Am Acad Dermatol. 1997 Sep;37(3 Pt 1):430-7 [9308559.001]
  • [Cites] Clin Plast Surg. 1997 Oct;24(4):627-36 [9342506.001]
  • [Cites] Clin Plast Surg. 1997 Oct;24(4):673-86 [9342510.001]
  • [Cites] J Cutan Pathol. 1998 Mar;25(3):153-9 [9550314.001]
  • [Cites] Br J Plast Surg. 1999 Jan;52(1):24-8 [10343586.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1766-72 [15541449.001]
  • [Cites] Semin Cutan Med Surg. 2004 Sep;23(3):167-73 [15584682.001]
  • [Cites] Cancer. 2005 Jul 1;104(1):170-5 [15929123.001]
  • [Cites] Br J Plast Surg. 2005 Sep;58(6):795-805 [16086990.001]
  • [Cites] J Am Acad Dermatol. 2005 Sep;53(3):464-8 [16112354.001]
  • [Cites] J Plast Reconstr Aesthet Surg. 2007;60(1):41-7 [17126265.001]
  • [Cites] Eur J Dermatol. 2000 Jun;10(4):315-6 [10939863.001]
  • [Cites] Br J Oral Maxillofac Surg. 2000 Oct;38(5):477-9 [11010777.001]
  • [Cites] J Natl Compr Canc Netw. 2004 Jan;2(1):2 [19777690.001]
  • (PMID = 18992138.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 55
  • [Other-IDs] NLM/ PMC2585560
  •  go-up   go-down


39. Schouten HW, Knippels MC, Franken RJ: [Maggots in the wound, debridement, disinfection and wound healing]. Ned Tijdschr Geneeskd; 2009;153:A624
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Vliegenmaden in de wond: débridement, desinfectie en wondgenezing.
  • An 87-year-old man had a longstanding untreated large basosquamous carcinoma on his right ear.
  • A striking finding was that the smell of the wound had disappeared and that the wound was much cleaner, with a reddish aspect and less necrosis.
  • [MeSH-minor] Aged, 80 and over. Animals. Carcinoma, Basosquamous / complications. Carcinoma, Basosquamous / parasitology. Carcinoma, Basosquamous / surgery. Ear Neoplasms / complications. Ear Neoplasms / parasitology. Ear Neoplasms / surgery. Humans. Larva. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19900320.001).
  • [ISSN] 1876-8784
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


40. Akyol M, Ozçelik S: Non-acne dermatologic indications for systemic isotretinoin. Am J Clin Dermatol; 2005;6(3):175-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diseases such as psoriasis, pityriasis rubra pilaris, condylomata acuminata, skin cancers, rosacea, hidradenitis suppurativa, granuloma annulare, lupus erythematosus and lichen planus have been shown to respond to the immunomodulatory, anti-inflammatory and antitumor activities of the drug.
  • Isotretinoin also helps prevent skin cancers such as basal cell carcinoma or squamous cell carcinoma.
  • A combination of systemic isotretinoin and interferon-alpha-2a may provide a more potent effect than isotretinoin alone in the prevention and treatment of skin cancers.Systemic isotretinoin may be considered as an alternative drug in some dermatologic diseases unresponsive to conventional treatment modalities.
  • [MeSH-major] Anti-Infective Agents / therapeutic use. Anti-Inflammatory Agents / therapeutic use. Dermatologic Agents / therapeutic use. Isotretinoin / therapeutic use. Skin Diseases / drug therapy
  • [MeSH-minor] Acne Vulgaris / drug therapy. Anti-Bacterial Agents / therapeutic use. Condylomata Acuminata / drug therapy. Drug Therapy, Combination. Granuloma Annulare / drug therapy. Hidradenitis Suppurativa / drug therapy. Humans. Keratolytic Agents / therapeutic use. Lichen Planus / drug therapy. Lupus Erythematosus, Systemic / drug therapy. Pityriasis Rubra Pilaris / drug therapy. Psoriasis / drug therapy. Rosacea / drug therapy. Sebaceous Glands / drug effects. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943494.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Infective Agents; 0 / Anti-Inflammatory Agents; 0 / Dermatologic Agents; 0 / Keratolytic Agents; EH28UP18IF / Isotretinoin
  • [Number-of-references] 133
  •  go-up   go-down


41. Ishihara K, Saida T, Otsuka F, Yamazaki N, Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society: Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update. Int J Clin Oncol; 2008 Feb;13(1):33-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update.
  • BACKGROUND: In the previous report of the Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society, we tabulated data on patients with malignant melanoma who had been registered at major medical institutions (22 institutions on average) in Japan over 5-year periods from 1987 to 1991 (group A) and from 1992 to 1996 (group B).
  • In the present study, patients registered from 1997 to 2001 (group C) were investigated and the data were compared with findings obtained by the subsequent follow-up of groups A and B.
  • Because the International Union Against Cancer (UICC) TNM and stage classifications for malignant melanoma were changed substantially in 2002, analyses in the present investigation were performed according to the new classifications.
  • In addition, the numbers of patients with various kinds of skin malignancies, including not only malignant melanoma but also basal cell carcinoma, squamous cell carcinoma, mycosis fungoides, actinic keratosis, Bowen's disease, and Paget's disease, registered at approximately 100 medical institutions in Japan from 1987 to 2001, were also investigated and data were tabulated.
  • RESULTS: The nationwide survey of Japanese patients with malignant skin tumors from 1987 to 2001 showed that the most prevalent skin tumor was basal cell carcinoma, which increased year by year, followed by squamous cell carcinoma, and then by malignant melanoma.
  • The following results were obtained from the data for melanoma patients registered at major institutions from 1987 to 2001. (1) The overall 10-year survival rates for melanoma patients in each chronological group were ranked as: group C > B > A, although only the difference between groups C and A was statistically significant. (2) The male-to-female ratio ranged from 1: 0.97 to 1: 1.14, and the survival rate of female patients was higher than that of male patients (the 140-month survival rate was 70.6% in females and 60% in males). (3) Assessment of the age distribution showed that the number of patients increased rapidly from ages 40-49 years and reached a peak at around 60 years in all three groups. (4) The sole of the foot was the most common site of melanoma in both males and females, while melanomas on the lower limbs were also prevalent in females. (5) Acral lentiginous melanoma (ALM) was the most common type in all three groups, accounting for nearly 50% of the patients in each group.
  • The prognosis of NM was the worst, while that of SSM was the most favorable. (6) The proportion of stage I patients was larger in group C than in groups A and B, but no significant difference among the groups was observed in the proportions of stage II, III, and IV patients.
  • For patients in stage IV, the survival rate in group C was slightly lower than that in group A or B. (7) In group C, the overall survival rates for substages III A, B, and C were ranked as III A > III B > III C. (8) The overall survival rates for stage IV M1a, M1b, and M1c were ranked as M1a > M1b > M1c.
  • CONCLUSION: In Japan, the number of patients with malignant skin tumors has increased year by year.
  • The prognosis of patients with advanced malignant melanoma remains extremely poor, but that of patients in stage III has shown an improvement.
  • [MeSH-major] Melanoma / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Epidemiol. 1995 Oct;24(5):897-907 [8557445.001]
  • [Cites] Int J Clin Oncol. 2003 Jun;8(3):139-50 [12851837.001]
  • [Cites] Int J Clin Oncol. 2001 Jun;6(3):109-16 [11706778.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1484-91 [10717634.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3635-48 [11504745.001]
  • [Cites] Harefuah. 1995 Jun 15;128(12):745-51, 824 [7557679.001]
  • (PMID = 18307017.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


42. Malejczyk M, Józwiak J, Jablonska S, Pfister H, Majewski S, Malejczyk J: Circulating soluble tumour necrosis factor receptors in patients with epidermodysplasia verruciformis as compared to patients with cutaneous tumours in the general population. Oncol Rep; 2005 Jan;13(1):151-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Soluble tumour necrosis factor receptors type I and II (sTNF-RI and II) were evaluated in sera from patients with epidermodysplasia verruciformis and patients with cutaneous warts, actinic keratoses, squamous cell carcinomas or basal cell carcinomas by specific enzyme-linked immunobiological assays.
  • The levels of sTNF-RI were significantly increased in patients with multiple actinic keratoses, squamous cell carcinoma and basal cell carcinoma.
  • [MeSH-major] Epidermodysplasia Verruciformis / diagnosis. Receptors, Tumor Necrosis Factor, Type I / blood. Receptors, Tumor Necrosis Factor, Type II / blood
  • [MeSH-minor] Adult. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Skin Neoplasms / diagnosis. Skin Neoplasms / metabolism

  • Genetic Alliance. consumer health - Epidermodysplasia Verruciformis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15583817.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Receptors, Tumor Necrosis Factor, Type I; 0 / Receptors, Tumor Necrosis Factor, Type II
  •  go-up   go-down


43. Sengupta SR, Das NK, Datta PK: Pathogenesis, clinical features and pathology of chronic arsenicosis. Indian J Dermatol Venereol Leprol; 2008 Nov-Dec;74(6):559-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Arsenicosis is a multisystem disorder, with virtually no system spared from its vicious claw; though its predominant manifestations are linked to cutaneous involvement.
  • Cutaneous effects take the form of pigmentary changes, hyperkeratosis, and skin cancers (Bowen's disease, squamous cell carcinoma, and basal cell epithelioma).
  • Peripheral vascular disease (blackfoot disease), hypertension, ischemic heart disease, noncirrhotic portal hypertension, hepatomegaly, peripheral neuropathy, respiratory and renal involvement, bad obstetrical outcome, hematological disturbances, and diabetes mellitus are among the other clinical features linked to arsenic toxicity.
  • Understandably the detoxification/bio-inactivation process is not a complete defense against the vicious metalloid, and it can cause chromosomal aberration, impairment of DNA repair process, alteration in the activity of tumor suppressor gene, etc., leading to genotoxicity and carcinogenicity.
  • Increased expression of cytokeratins, keratin-16 (marker for hyperproliferation) and keratin-8 and -18 (marker for less differentiated epithelial cells), can be related to the histopathological findings of hyperkeratosis and dysplastic cells in the arsenicosis skin lesion.
  • [MeSH-major] Arsenic Poisoning / epidemiology. Arsenic Poisoning / pathology. Skin Diseases / epidemiology. Skin Diseases / pathology
  • [MeSH-minor] Animals. Arsenic / adverse effects. Chronic Disease. Environmental Exposure / adverse effects. Humans. Water Pollutants / adverse effects. World Health Organization

  • MedlinePlus Health Information. consumer health - Arsenic.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19171978.001).
  • [ISSN] 0973-3922
  • [Journal-full-title] Indian journal of dermatology, venereology and leprology
  • [ISO-abbreviation] Indian J Dermatol Venereol Leprol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Water Pollutants; N712M78A8G / Arsenic
  • [Number-of-references] 115
  •  go-up   go-down


44. Rollison DE, Pawlita M, Giuliano AR, Iannacone MR, Sondak VK, Messina JL, Cruse CW, Fenske NA, Glass LF, Kienstra M, Michael KM, Waterboer T, Gheit T, Tommasino M: Measures of cutaneous human papillomavirus infection in normal tissues as biomarkers of HPV in corresponding nonmelanoma skin cancers. Int J Cancer; 2008 Nov 15;123(10):2337-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measures of cutaneous human papillomavirus infection in normal tissues as biomarkers of HPV in corresponding nonmelanoma skin cancers.
  • Cutaneous human papillomavirus (HPV) may be associated with the development of nonmelanoma skin cancer (NMSC), as suggested by reports of HPV DNA in NMSC tumors.
  • NMSC tumor tissue was obtained from 20 patients with pathology-confirmed basal or squamous cell carcinoma of the skin, in addition to several normal tissues, including eyebrow hairs, normal skin swabs obtained using multiple techniques, normal skin punch and shave biopsies, and serum for antibody measurement.
  • Using HPV DNA in tumor tissues as a gold standard, sensitivity and specificity were calculated for each measure of HPV infection in normal tissues. beta-Papillomavirus DNA was observed in tumor tissues in 60% of patients.
  • The normal skin punch biopsy demonstrated optimal sensitivity (75%) and specificity (75%).
  • [MeSH-major] Biomarkers / metabolism. Papillomavirus Infections / virology. Skin Diseases, Viral / virology. Skin Neoplasms / virology
  • [MeSH-minor] Betapapillomavirus / isolation & purification. Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / virology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / virology. Enzyme-Linked Immunosorbent Assay. Humans. Risk Factors

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18729188.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


45. Heneghan MK, Hazan C, Halpern AC, Oliveria SA: Skin cancer coverage in a national newspaper: a teachable moment. J Cancer Educ; 2007;22(2):99-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin cancer coverage in a national newspaper: a teachable moment.
  • BACKGROUND: The objectives of this study were to (1) identify the number of published articles related to skin cancer in The New York Times newspaper from 1980-2004;.
  • (2) assess the content of the articles related to skin cancer, and (3) examine the trends in media coverage of skin cancer over time.
  • METHODS: We performed a content analysis on articles related to skin cancer appearing in The New York Times during January 1, 1980, through December 31, 2004, using the ProQuest online content repository database and key words skin cancer.
  • We conducted an advanced focus search of all "skin cancer" articles using key words "melanoma," "squamous cell carcinoma," "basal cell carcinoma," "sunscreen," "tanning," "sunbathing," and "tanning salon".
  • RESULTS: We identified 874 published articles relating to skin cancer.
  • Coverage of other major subjects included sunscreen (11%), tanning (9%), basal cell carcinoma (7%), squamous cell carcinoma (3%), sunbathing (2%), and tanning salon (2%).
  • The remaining 37% of articles contained some mention of skin cancer, but skin cancer was not the main topic nor were any of the focus terms.
  • Over the 25-year period we examined, there was a slight upward trend in the number of skin-cancer-related articles, although we observed year-to-year variation.
  • CONCLUSIONS: Understanding how the print media portrays skin cancer issues provides valuable feedback for federal agencies and cancer organizations and may ultimately help promote skin cancer prevention and education.
  • [MeSH-major] Bibliometrics. Health Education. Journalism, Medical. Newspapers as Topic. Skin Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Health Commun. 2000 Apr-Jun;5(2):117-34 [11010345.001]
  • [Cites] Breast Cancer Res Treat. 2000 Jul;62(1):71-9 [10989987.001]
  • [Cites] Am J Public Health. 1989 Nov;79(11):1551-2 [2683815.001]
  • [Cites] AIDS Educ Prev. 1992 Winter;4(4):295-307 [1472415.001]
  • [Cites] Adolescence. 1996 Summer;31(122):253-64 [8726887.001]
  • [Cites] J Am Acad Dermatol. 1986 Apr;14(4):676-9 [3958278.001]
  • [Cites] J Commun. 1975 Summer;25(3):171-3 [1184780.001]
  • [Cites] J Am Acad Dermatol. 1997 Aug;37(2 Pt 1):179-86 [9270501.001]
  • [Cites] Arch Dermatol. 2005 Apr;141(4):491-6 [15837868.001]
  • [Cites] Addiction. 1997 Jun;92 Suppl 2:S189-99 [9231444.001]
  • [Cites] Prev Med. 2005 Aug;41(2):511-20 [15917047.001]
  • [Cites] Clin Exp Dermatol. 1993 Sep;18(5):396-400 [8252756.001]
  • [Cites] Am J Prev Med. 2004 Jul;27(1):57-65 [15212776.001]
  • [Cites] Health Educ Q. 1996 Aug;23(3):346-64 [8841819.001]
  • [Cites] Public Health Rep. 1982 Mar-Apr;97(2):113-5 [7063590.001]
  • [Cites] J Womens Health Gend Based Med. 2000 Jun;9(5):471-5 [10883937.001]
  • [Cites] J Am Acad Dermatol. 1996 Jun;34(6):971-8 [8647990.001]
  • [Cites] Prev Med. 1992 Sep;21(5):654-69 [1438112.001]
  • [Cites] Arch Intern Med. 1989 Jan;149(1):140-4 [2912403.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1180-3 [1891034.001]
  • [Cites] J Am Diet Assoc. 1977 Nov;71(5):505-9 [615901.001]
  • [Cites] Am J Public Health. 1992 Oct;82(10):1374-6 [1415863.001]
  • [Cites] J Community Health. 1992 Jun;17(3):153-65 [1512306.001]
  • [Cites] J Clin Epidemiol. 1993 Sep;46(9):987-1001 [8263584.001]
  • [Cites] Eval Rev. 1996 Aug;20(4):404-23 [10183257.001]
  • [Cites] Arch Intern Med. 2003 Jul 14;163(13):1601-5 [12860585.001]
  • [Cites] Lancet. 1996 Jun 8;347(9015):1600-3 [8667872.001]
  • [Cites] J Pediatr Psychol. 1994 Feb;19(1):3-17; discussion 19-26 [8151494.001]
  • [Cites] Tob Control. 2003 Sep;12 Suppl 2:ii75-81 [12878777.001]
  • [Cites] J Am Acad Dermatol. 1999 Jul;41(1):81-99 [10411417.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] N Engl J Med. 1998 Jul 9;339(2):87-92 [9654540.001]
  • [Cites] JAMA. 1998 Mar 11;279(10):762-6 [9508152.001]
  • (PMID = 17605623.001).
  • [ISSN] 0885-8195
  • [Journal-full-title] Journal of cancer education : the official journal of the American Association for Cancer Education
  • [ISO-abbreviation] J Cancer Educ
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K07 CA94002
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  •  go-up   go-down


46. Kim GK, Del Rosso JQ, Bellew S: Skin cancer in asians: part 1: nonmelanoma skin cancer. J Clin Aesthet Dermatol; 2009 Aug;2(8):39-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin cancer in asians: part 1: nonmelanoma skin cancer.
  • Since the 1960s, basal cell carcinoma and squamous cell carcinoma among the Caucasian population have increased 3 to 8 percent annually.
  • Although Asians display relative protection from basal cell carcinoma and squamous cell carcinoma, incidence rates of these nonmelanoma skin cancers have been increasing over the past three decades.
  • With changing demographics and a steady rise in the minority population in the United States, there is an increased need for further studies of cutaneous malignancies within Asian and other ethnic populations.
  • This article reviews nonmelanoma skin cancers in the Asian population with an insight into contributing factors, such as skin type, occupation, cultural practices, and genetic components.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Photochem Photobiol. 2008 Jan-Feb;84(1):63-6 [18173702.001]
  • [Cites] Science. 1991 Jul 5;253(5015):49-53 [1905840.001]
  • [Cites] J Am Acad Dermatol. 2006 Nov;55(5):741-60; quiz 761-4 [17052479.001]
  • [Cites] Photochem Photobiol Sci. 2006 Feb;5(2):208-14 [16465307.001]
  • [Cites] Ann Surg. 1965 Feb;161:170-88 [14260013.001]
  • [Cites] Med Oncol. 1999 Jul;16(2):86-94 [10456656.001]
  • [Cites] Arch Dermatol. 1999 Jul;135(7):843-4 [10411160.001]
  • [Cites] J Am Acad Dermatol. 1990 Sep;23(3 Pt 1):413-21 [2212139.001]
  • [Cites] Arch Dermatol. 1988 Jun;124(6):869-71 [3377516.001]
  • [Cites] J Dermatol. 1984 Aug;11(4):313-21 [6392379.001]
  • [Cites] J Dermatol. 1990 Jun;17(6):342-6 [2384636.001]
  • [Cites] Plast Reconstr Surg. 1978 Sep;62(3):407-14 [693668.001]
  • [Cites] Ann Dermatol Venereol. 2003 Apr;130(4):413-6 [12843850.001]
  • [Cites] Br J Dermatol. 2001 Apr;144(4):841-8 [11298546.001]
  • [Cites] J Epidemiol. 1999 Dec;9(6 Suppl):S14-21 [10709346.001]
  • [Cites] Arch Dermatol. 1999 Jul;135(7):781-6 [10411152.001]
  • [Cites] J Dermatol Sci. 1999 Apr;19(3):161-5 [10215187.001]
  • [Cites] J Dermatol Sci. 1997 Nov;16(1):74-8 [9438911.001]
  • [Cites] J Dermatol Sci. 1997 Sep;15(3):183-7 [9302646.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 1996 Feb;12(1):22-6 [8884895.001]
  • [Cites] J Trauma. 1997 Jan;42(1):104-7 [9003266.001]
  • [Cites] Am J Dermatopathol. 2006 Dec;28(6):472-7 [17122490.001]
  • [Cites] J Surg Oncol. 1996 Feb;61(2):124-30 [8606543.001]
  • [Cites] Dermatol Surg. 1996 Mar;22(3):217-26 [8599733.001]
  • [Cites] Dermatol Clin. 1995 Jul;13(3):583-94 [7554506.001]
  • [Cites] J Invest Dermatol. 1994 Apr;102(4):440-4 [8151121.001]
  • [Cites] Recent Results Cancer Res. 1995;139:263-73 [7597297.001]
  • [Cites] Int J Cancer. 1993 Apr 1;53(6):886-91 [8473047.001]
  • [Cites] Am J Epidemiol. 1996 Dec 1;144(11):1034-40 [8942434.001]
  • (PMID = 20729955.001).
  • [ISSN] 1941-2789
  • [Journal-full-title] The Journal of clinical and aesthetic dermatology
  • [ISO-abbreviation] J Clin Aesthet Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2923966
  •  go-up   go-down


47. Kimball KJ, Straughn JM, Conner MG, Kirby TO: Recurrent basosquamous cell carcinoma of the vulva. Gynecol Oncol; 2006 Aug;102(2):400-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent basosquamous cell carcinoma of the vulva.
  • BACKGROUND: Basosquamous cell carcinoma (BSC) of the vulva is a rare entity with interesting prognostic and therapeutic implications.
  • CONCLUSION: BSC is a rare disorder of the vulva.
  • The metastatic potential of this tumor is not fully understood, but likely is intermediate between squamous cell carcinoma and basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basosquamous / pathology. Carcinoma, Basosquamous / surgery. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Vulvar Neoplasms / pathology. Vulvar Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16624392.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Snarskaia ES, Molochkov VA, Frank GA, Zavalishina LA: [Matrix metalloproteinases and their tissue inhibitors in basal cell and metatypical cancer of the skin]. Arkh Patol; 2005 May-Jun;67(3):14-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Matrix metalloproteinases and their tissue inhibitors in basal cell and metatypical cancer of the skin].
  • 10 cases of ulcerative-nodular basal cell carcinoma and 10 cases of metatypical carcinoma of the skin were studied immunohistochemically for immunoexpression of matrix metalloproteinases (MMP-1, MMP-9) and their endogenic tissue inhibitors (TIMP-1, TIMP-2) in combination with PCNA, p53 tumor complexes.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Matrix Metalloproteinase 1 / analysis. Matrix Metalloproteinase 9 / analysis. Skin Neoplasms / diagnosis. Tissue Inhibitor of Metalloproteinases / analysis
  • [MeSH-minor] Diagnosis, Differential. Humans. Proliferating Cell Nuclear Antigen / analysis. Tissue Inhibitor of Metalloproteinase-1 / analysis. Tissue Inhibitor of Metalloproteinase-2 / analysis. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16075605.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen; 0 / Tissue Inhibitor of Metalloproteinase-1; 0 / Tissue Inhibitor of Metalloproteinases; 0 / Tumor Suppressor Protein p53; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


49. Hernández-Martín A, Arias-Palomo D, Barahona E, Hidalgo C, Muñoz C, García-Higuera I: [Analysis of surgical treatment for nonmelanoma skin cancer performed by dermatologists in a public hospital: clinical-pathological correlation, use of hospital resources, and waiting list time from diagnosis]. Actas Dermosifiliogr; 2007 Dec;98(10):694-701
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of surgical treatment for nonmelanoma skin cancer performed by dermatologists in a public hospital: clinical-pathological correlation, use of hospital resources, and waiting list time from diagnosis].
  • [Transliterated title] Análisis del tratamiento quirúrgico del cáncer cutáneo no melanoma cuando es realizado por dermatólogos en un hospital público: correlación anatomoclínica, empleo de recursos hospitalarios y tiempo de espera desde el diagnóstico.
  • BACKGROUND: Nonmelanoma skin cancer is the most common form of cancer in humans.
  • No studies have been published addressing differences in the management of surgical treatment for nonmelanoma skin cancer according to the specialties involved.
  • OBJECTIVES: To assess the preoperative diagnostic accuracy and the use of health care resources when surgical treatment of nonmelanoma skin cancer is done by dermatologists belonging to the Spanish national health service.
  • METHODS: A prospective observational study was carried out over a period of 36 months using data corresponding to all patients diagnosed with nonmelanoma skin cancer and treated surgically in the Dermatology Department of Complejo Hospitalario de Burgos, Spain.
  • Data were analyzed for clinical-pathological correlation, complexity of the intervention, use of health care resources, and time elapsed between clinical diagnosis and surgery.
  • RESULTS: The study included 448 patients and 521 skin lesions suspected to be nonmelanoma skin cancer (basal cell carcinoma or squamous cell carcinoma).
  • Diagnosis was exclusively clinical in 487 tumors and a clinical-pathological correlation of 84.39% was observed.
  • In 349 patients (77.90%) the procedure was performed on an outpatient basis, 73 (16.29%) required a short stay in the surgical day care unit, and 26 (5.80%) required hospital admission.
  • The mean (SD) delay from clinical diagnosis to surgery was 68.44 (42.22) days, with a median delay of 60 days.
  • CONCLUSIONS: Dermatology specialists are highly qualified to diagnose malignant skin tumors and accurately identify those patients requiring surgery.
  • [MeSH-major] Skin Neoplasms / pathology. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Actas Dermosifiliogr. 2008 Mar;99(2):170
  • (PMID = 18035027.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


50. Abdulla FR, Kerns MJ, Mutasim DF: Amelanotic lentigo maligna: a report of three cases and review of the literature. J Am Acad Dermatol; 2010 May;62(5):857-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Amelanotic lentigo maligna is not clinically suspected and is often mistaken for a basal cell carcinoma, squamous cell carcinoma, or dermatitis.
  • CONCLUSION: A high degree of clinical and histologic suspicion is required to make the diagnosis of this clinically nondescript neoplasm.
  • [MeSH-major] Hutchinson's Melanotic Freckle / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Basal Cell / diagnosis. Diagnosis, Differential. Female. Forearm. Humans. Keratosis, Actinic / diagnosis. Male. Middle Aged. Neck

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
  • (PMID = 19766347.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 11
  •  go-up   go-down


51. Bailey JS, Goldwasser MS: Surgical management of facial skin cancer. Oral Maxillofac Surg Clin North Am; 2005 May;17(2):205-33, vi
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management of facial skin cancer.
  • Surgical excision is the gold standard for management of cutaneous basal cell carcinoma or squamous cell carcinoma.
  • Surgical management of nonmelanotic facial skin cancer requires preoperative planning and an in-depth understanding of reconstructive techniques, including primary closure, skin grafting, and local tissue flaps.
  • The decision regarding the method of treatment of nonmelanotic skin cancer is highly individualized and depends on patient age, cancer size, histologic subtype, and site.
  • In this article we discuss the principles and techniques of surgical excision and reconstruction of site-specific facial skin cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18088778.001).
  • [ISSN] 1042-3699
  • [Journal-full-title] Oral and maxillofacial surgery clinics of North America
  • [ISO-abbreviation] Oral Maxillofac Surg Clin North Am
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Gass JK, Chan SK, Rytina E, Greenberg DC, Burrows NP: Multiple primary malignancies in patients with Merkel cell carcinoma. J Eur Acad Dermatol Venereol; 2010 May;24(5):601-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple primary malignancies in patients with Merkel cell carcinoma.
  • BACKGROUND: Merkel cell carcinoma (MCC) is a rare malignant cutaneous tumour, the incidence of which is increasing.
  • OBJECTIVES: We report the rate and nature of multiple malignancies in patients with MCC treated over a 10 year period in Addenbrooke's Hospital in Cambridge, United Kingdom, as well as the temporal relationship of these additional malignancies to the diagnosis of MCC.
  • RESULTS: The 27 patients had an approximately equal sex incidence with a median age at diagnosis of 79 years.
  • Seventy percent (n=19) of patients had a second primary malignant tumour; and 7 of these patients had two or more tumours in addition to the MCC.
  • Eighteen patients had additional cutaneous malignancies: melanoma, squamous cell carcinoma and basal cell carcinoma, and 8 patients presented non-cutaneous malignancy including colorectal, haematological and breast tumours.
  • Of the 28 additional tumours in our patients, half were diagnosed prior to presentation of MCC, 32% within 6 months of diagnosis, and 18% between 6 months and 3 years after diagnosis.
  • CONCLUSIONS: Our figures reflect a higher incidence of multiple malignancies in those with Merkel cell tumour than has previously been reported.
  • [MeSH-major] Carcinoma, Merkel Cell / complications. Neoplasms, Multiple Primary / complications. Skin Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19900177.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


53. Rector A, Mostmans S, Van Doorslaer K, McKnight CA, Maes RK, Wise AG, Kiupel M, Van Ranst M: Genetic characterization of the first chiropteran papillomavirus, isolated from a basosquamous carcinoma in an Egyptian fruit bat: the Rousettus aegyptiacus papillomavirus type 1. Vet Microbiol; 2006 Oct 31;117(2-4):267-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic characterization of the first chiropteran papillomavirus, isolated from a basosquamous carcinoma in an Egyptian fruit bat: the Rousettus aegyptiacus papillomavirus type 1.
  • The complete genomic DNA of a novel papillomavirus (PV) was isolated from a basosquamous carcinoma on the wing of an Egyptian fruit bat (Rousettus aegyptiacus).
  • Since RaPV-1 is only distantly related to other papillomaviruses (with maximally 50% nucleotide sequence identity across the L1 open reading frame), it cannot be assigned to one of the existing papillomavirus genera and therefore represents the first member of a novel, as yet unnamed, close-to-root papillomavirus genus.
  • [MeSH-major] Carcinoma, Basosquamous / veterinary. Chiroptera / virology. Papillomaviridae / genetics. Papillomaviridae / isolation & purification. Papillomavirus Infections / veterinary. Skin Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16854536.001).
  • [ISSN] 0378-1135
  • [Journal-full-title] Veterinary microbiology
  • [ISO-abbreviation] Vet. Microbiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Transposable Elements; 0 / DNA, Viral
  •  go-up   go-down


54. Ostler DA, Prieto VG, Reed JA, Deavers MT, Lazar AJ, Ivan D: Adipophilin expression in sebaceous tumors and other cutaneous lesions with clear cell histology: an immunohistochemical study of 117 cases. Mod Pathol; 2010 Apr;23(4):567-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adipophilin expression in sebaceous tumors and other cutaneous lesions with clear cell histology: an immunohistochemical study of 117 cases.
  • This study examines adipophilin expression in various sebaceous lesions and other cutaneous tumors with a clear cell histology that may mimic sebaceous differentiation.
  • A total of 117 cutaneous clear cell lesions including 16 sebaceous adenomas, 25 sebaceous carcinomas, 8 basal cell carcinomas, 12 squamous cell carcinomas, 6 xanthomas, 10 xanthelasmas, 10 xanthogranulomas, 4 balloon cell nevi, 5 trichilemmomas, 8 clear cell hidradenomas, and 13 metastatic renal cell carcinomas were examined using immunohistochemistry for the expression of adipophilin.
  • Adipophilin was expressed in 16 of 16 (100%) sebaceous adenomas, 23 of 25 (92%) sebaceous carcinomas, 10 of 10 (100%) xanthelasmas, 9 of 10 (90%) xanthogranulomas, 6 of 6 (100%) xanthomas, and 9 of 13 (62.5%) metastatic renal cell carcinomas.
  • Adipophilin expression was not seen in any of the other lesions with clear cell histology, basal cell carcinomas, or squamous cell carcinomas, including cases that had focal clear cell differentiation.
  • Adipophilin can be valuable in an immunohistochemical panel when evaluating cutaneous lesions with clear cell histology as it identifies intracytoplasmic lipid vesicles in sebaceous and xanthomatous lesions.
  • In periocular lesions, it is effective in helping to exclude basal cell carcinoma and squamous cell carcinoma when sebaceous carcinoma is under consideration.
  • Adipophilin expression is not as useful for the differential diagnosis that includes metastatic renal cell carcinoma, a rare but important, diagnostic differential.
  • [MeSH-major] Biomarkers, Tumor / analysis. Peptides / metabolism. Sebaceous Gland Neoplasms / metabolism. Sebaceous Gland Neoplasms / pathology. Skin Neoplasms / metabolism. Skin Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Infant. Male. Membrane Proteins. Middle Aged. Neoplasms, Adnexal and Skin Appendage / metabolism. Neoplasms, Adnexal and Skin Appendage / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20118912.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Proteins; 0 / Peptides; 0 / perilipin 2
  •  go-up   go-down


55. Beljaards RC, Kirtschig G, Boorsma DM: Expression of neural cell adhesion molecule (CD56) in basal and squamous cell carcinoma. Dermatol Surg; 2008 Nov;34(11):1577-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of neural cell adhesion molecule (CD56) in basal and squamous cell carcinoma.
  • [MeSH-major] Antigens, CD56 / biosynthesis. Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18798745.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56
  •  go-up   go-down


56. Panda S: Nonmelanoma skin cancer in India: current scenario. Indian J Dermatol; 2010 Oct;55(4):373-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonmelanoma skin cancer in India: current scenario.
  • Incidence of skin cancers has been increasing since the last few decades worldwide.
  • Nonmelanoma skin cancer (NMSC) is the commonest variety of cutaneous malignancy.
  • Conventional wisdom has it that the incidence of all varieties of skin cancers is lower among Indians due to the protective effects of melanin.
  • Reports of quite a few atypical cases lead us to hypothesize that factors other than ultraviolet radiation may be important in the occurrences of these cancers, particularly in the skin types prevalent in India.
  • The descriptive epidemiology and clinical characteristics of squamous and basal cell carcinoma in India, including their variants, are discussed here along with hypotheses on their etiopathogenesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 2000 Jul;43(1 Pt 1):138-50 [10863242.001]
  • [Cites] Arch Dermatol. 2000 Jun;136(6):800 [10871955.001]
  • [Cites] Australas J Dermatol. 1997 Jun;38 Suppl 1:S31-5 [10994469.001]
  • [Cites] Cancer. 1975 Mar;35(3):600-5 [1111931.001]
  • [Cites] J Am Acad Dermatol. 2001 Mar;44(3):462-70 [11209116.001]
  • [Cites] J Am Acad Dermatol. 2001 Mar;44(3):497-9 [11209121.001]
  • [Cites] Hautarzt. 2002 Feb;53(2):118-20 [11963191.001]
  • [Cites] Am J Dermatopathol. 2002 Apr;24(2):144-8 [11979075.001]
  • [Cites] N Engl J Med. 1992 Dec 3;327(23):1649-62 [1435901.001]
  • [Cites] Cancer. 1992 Jul 1;70(1):104-8 [1606530.001]
  • [Cites] J Am Acad Dermatol. 1992 Jun;26(6):976-90 [1607418.001]
  • [Cites] Ann Univ Mariae Curie Sklodowska Med. 2004;59(2):498-502 [16146137.001]
  • [Cites] Indian J Dermatol Venereol Leprol. 2005 Nov-Dec;71(6):414-6 [16394484.001]
  • [Cites] Indian J Dermatol Venereol Leprol. 2005 Nov-Dec;71(6):430-1 [16394491.001]
  • [Cites] Indian J Dermatol Venereol Leprol. 2007 Mar-Apr;73(2):127-8 [17456927.001]
  • [Cites] Arch Dermatol Res. 2008 Apr;300 Suppl 1:S43-50 [17985102.001]
  • [Cites] Int J Dermatol. 2008 Jan;47(1):59-60 [18173605.001]
  • [Cites] Indian J Dermatol Venereol Leprol. 2008 Nov-Dec;74(6):662-4 [19172004.001]
  • [Cites] CA Cancer J Clin. 1991 Jan-Feb;41(1):19-36 [1984806.001]
  • [Cites] Indian J Dermatol. 2008;53(3):137-9 [19882013.001]
  • [Cites] Indian J Dermatol. 2008;53(3):140-1 [19882014.001]
  • [Cites] Indian J Dermatol. 2008;53(4):192-4 [19882033.001]
  • [Cites] J Am Acad Dermatol. 1991 Jan;24(1):1-13 [1999506.001]
  • [Cites] Indian J Dermatol. 2009;54(1):46-8 [20049269.001]
  • [Cites] Indian J Dermatol. 2009;54(2):196-9 [20101326.001]
  • [Cites] Indian J Dermatol. 2009;54(4):342-6 [20101335.001]
  • [Cites] Indian J Dermatol. 2010 Oct;55(4):363-6 [21430891.001]
  • [Cites] Indian J Dermatol. 2009 Jul;54(3):247-50 [20161856.001]
  • [Cites] Indian J Dermatol. 2009 Jul;54(3):225-8 [20161851.001]
  • [Cites] Indian J Dermatol. 2010 Oct;55(4):387-9 [21430898.001]
  • [Cites] Indian J Dermatol. 2009 Jul;54(3):283-6 [20161865.001]
  • [Cites] Indian J Dermatol. 2010 Apr-Jun;55(2):178-80 [20606890.001]
  • [Cites] Indian J Dermatol. 2010 Apr-Jun;55(2):201-4 [20606900.001]
  • [Cites] Indian J Dermatol Venereol Leprol. 2010 Jul-Aug;76(4):420-2 [20657132.001]
  • [Cites] J Am Acad Dermatol. 1990 Sep;23(3 Pt 1):413-21 [2212139.001]
  • [Cites] J Am Acad Dermatol. 1990 Dec;23(6 Pt 1):1118-26 [2273112.001]
  • [Cites] N Engl J Med. 1989 Dec 7;321(23):1577-83 [2511446.001]
  • [Cites] Histopathology. 1989 Feb;14(2):129-39 [2540085.001]
  • [Cites] J Am Acad Dermatol. 1988 Feb;18(2 Pt 1):292-8 [3346413.001]
  • [Cites] Arch Dermatol. 1988 Aug;124(8):1244-5 [3401029.001]
  • [Cites] Cancer. 1987 Jul 1;60(1):118-20 [3581025.001]
  • [Cites] Cancer. 1974 Oct;34(4):1333-8 [4422100.001]
  • [Cites] Ann Surg. 1973 Jan;177(1):1-7 [4682500.001]
  • [Cites] J Surg Oncol. 1973 May;5(5):431-63 [4752463.001]
  • [Cites] Arch Dermatol. 1971 Aug;104(2):124-7 [5093166.001]
  • [Cites] J Am Acad Dermatol. 1980 Feb;2(2):155-60 [6245113.001]
  • [Cites] J Am Acad Dermatol. 1983 Oct;9(4):487-502 [6355213.001]
  • [Cites] Am J Dermatopathol. 1984 Apr;6(2):187-93 [6375422.001]
  • [Cites] Cancer Invest. 1983;1(2):119-26 [6667401.001]
  • [Cites] Cancer. 1983 Jul 1;52(1):173-5 [6850540.001]
  • [Cites] Cancer. 1982 Jan 15;49(2):350-3 [7053833.001]
  • [Cites] Cancer. 1981 Mar 15;47(6):1436-8 [7226069.001]
  • [Cites] J Am Acad Dermatol. 1981 Nov;5(5):535-43 [7298919.001]
  • [Cites] Clin Plast Surg. 1980 Jul;7(3):301-11 [7438701.001]
  • [Cites] Arch Dermatol. 1998 Mar;134(3):333-7 [9580120.001]
  • [Cites] JAMA. 1977 Aug 8;238(6):513 [327111.001]
  • (PMID = 21430894.001).
  • [ISSN] 1998-3611
  • [Journal-full-title] Indian journal of dermatology
  • [ISO-abbreviation] Indian J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3051301
  • [Keywords] NOTNLM ; Squamous cell carcinoma / basal cell carcinoma / nonmelanoma skin cancer
  •  go-up   go-down


57. Leibovitch I, Huilgol SC, Selva D, Lun K, Richards S, Paver R: Microcystic adnexal carcinoma: treatment with Mohs micrographic surgery. J Am Acad Dermatol; 2005 Feb;52(2):295-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microcystic adnexal carcinoma: treatment with Mohs micrographic surgery.
  • BACKGROUND: Microcystic adnexal carcinoma (MAC) is reported to have a high rate of recurrence with standard wide local excision.
  • METHODS: This prospective, multi-center case series included all patients in Australia treated with MMS for MAC, who were monitored by the Skin and Cancer Foundation between 1993 and 2002.
  • In 31.8% of cases it was a recurrent tumor.
  • In 32.5% of cases the tumor was initially misdiagnosed as basal cell carcinoma or squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Skin Appendage / surgery. Mohs Surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Australia / epidemiology. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Child. Databases, Factual. Diagnostic Errors. Female. Follow-Up Studies. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / epidemiology. Head and Neck Neoplasms / surgery. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Prospective Studies. Retrospective Studies. Treatment Outcome


58. Son KD, Kim TJ, Lee YS, Park GS, Han KT, Lim JS, Kang CS: Comparative analysis of immunohistochemical markers with invasiveness and histologic differentiation in squamous cell carcinoma and basal cell carcinoma of the skin. J Surg Oncol; 2008 Jun 1;97(7):615-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of immunohistochemical markers with invasiveness and histologic differentiation in squamous cell carcinoma and basal cell carcinoma of the skin.
  • BACKGROUND: This study evaluates several tumor-related markers to examine the expression pattern of markers according to the invasiveness and histopathologic differentiation of squamous cell carcinoma and basal cell carcinoma.
  • METHODS: Ninety-four cases of squamous cell carcinoma and 108 cases of basal cell carcinoma using tissue array in order to determine correlations between the expression of Ki-67, p53, EGFR, CD44v6, MMP-1 and MMP-3, invasiveness and histologic differentiation.
  • RESULTS: The depth of invasion showed a correlation with CD44v6 expression of tumor cell in both squamous cell carcinoma and basal cell carcinoma (P = 0.009, P = 0.036, respectively) and with the MMP-1 expression of stromal cell in squamous cell carcinoma (P = 0.010).
  • The differentiation of squamous cell carcinoma was correlated with Ki-67 index.
  • The loss of palisading arrangement in basal cell carcinoma was correlated with the MMP-1 expression of stromal cells (P = 0.045).
  • CONCLUSIONS: CD44v6 and MMP-1, expressed in tumor cells and stromal cells respectively, are significant markers associated with the invasiveness of tumors in squamous cell carcinoma and basal cell carcinoma of the skin and that it will be helpful to evaluate the invasiveness by measuring the expression of these markers.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD44 / biosynthesis. Female. Genes, erbB-1. Humans. Immunohistochemistry. Ki-67 Antigen / biosynthesis. Male. Matrix Metalloproteinase 1 / biosynthesis. Matrix Metalloproteinase 3 / biosynthesis. Middle Aged. Neoplasm Invasiveness. Tumor Suppressor Protein p53 / biosynthesis


59. Stollery N: Basal and squamous cell carcinoma. Practitioner; 2006 Dec;250(1689):46, 48-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal and squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Psoriasis / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Eyelid Neoplasms / diagnosis. Humans

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17283757.001).
  • [ISSN] 0032-6518
  • [Journal-full-title] The Practitioner
  • [ISO-abbreviation] Practitioner
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 10
  •  go-up   go-down


60. Stoebner PE, Le Gallic L, Berthe ML, Boulle N, Lallemant B, Marque M, Gaspard C, Delfour C, Lavabre-Bertrand T, Martinez J, Meunier L: Decreased expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in basal cell carcinomas. Exp Dermatol; 2008 Nov;17(11):908-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in basal cell carcinomas.
  • Thymidine phosphorylase (TP)/platelet-derived endothelial cell growth factor is associated with tumor angiogenesis.
  • We evaluated the TP mRNA and protein expression in basal cell carcinomas (BCC) and in various skin tumors including numerous BCC histological simulants.
  • Immunohistochemistry was performed on 99 paraffin sections of formalin-fixed skin tumors using monoclonal antibodies (mAb) against TP.
  • TP mRNA levels were measured by real time RT-PCR in whole BCCs (wBCC) and laser capture microdissected (LCM) BCC tumor cells.
  • TP immunostaining was negative in all BCC variants and in most of the benign trichogeneic tumors studied.
  • By contrast, TP was constantly immunodetected in actinic keratosis (AK), squamous cell carcinomas (SCC), syringomatous carcinomas (SC), basosquamous carcinomas (BSC) and melanomas.
  • TP mRNA levels were low and statistically not different in wBCC and normal skin but were strongly downregulated in LCM-BCC as compared with LCM-normal epidermis.
  • We concluded that (i) anti-TP mAb is an useful marker to differentiate BCC from AK, SCC, BSC and SC but not from trichoblastic tumors, (ii) the lack of TP protein expression in BCC tumoral cells is linked to transcriptional regulatory mechanisms, (iii) the low TP mRNA levels in whole BCC may be related to the low intra-tumoral microvessel density, the slow growth and the very low metastatic potential of these tumors.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology. Thymidine Phosphorylase / genetics
  • [MeSH-minor] Carcinoma, Basosquamous / genetics. Carcinoma, Basosquamous / metabolism. Carcinoma, Basosquamous / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Down-Regulation. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Keratosis, Actinic / genetics. Keratosis, Actinic / metabolism. Keratosis, Actinic / pathology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18341568.001).
  • [ISSN] 1600-0625
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.4.2.4 / Thymidine Phosphorylase
  •  go-up   go-down


61. Massari LP, Kastelan M, Gruber F: Epidermal malignant tumors: pathogenesis, influence of UV light and apoptosis. Coll Antropol; 2007 Jan;31 Suppl 1:83-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal malignant tumors: pathogenesis, influence of UV light and apoptosis.
  • Basal cell carcinoma and squamous cell carcinoma, collectively termed non-melanoma skin cancers are the most common malignant tumors in humans.
  • Basal cell carcinoma grows slowly and metastatic spread is very rare.
  • Squamous cell carcinoma is characterized by infiltrative, destructive growth and metastasis.
  • Long-term exposure of skin to UV light has a great impact on development of these epidermal malignancies.
  • The major role in development of skin cancer is given to proapoptotic p53 molecule or tumor suppressor gene which mutation due to UV exposure leads to resistance of DNA-damaged cell to apoptosis.
  • Other proapoptotic molecules such as Fas ligand (FasL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) are strongly expressed in basal cell carcinoma and squamous cell carcinoma that could be explained by the ability of tumor to escape the attack of immune system.
  • [MeSH-major] Apoptosis. Carcinoma, Basal Cell / physiopathology. Carcinoma, Squamous Cell / physiopathology. Neoplasms, Radiation-Induced / physiopathology. Skin Neoplasms / physiopathology. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17469758.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Croatia
  • [Number-of-references] 29
  •  go-up   go-down


62. Tarstedt M, Larkö O, Molin L, Wennberg AM: [Increasing number of skin cancer cases--also among the younger]. Lakartidningen; 2005 Jun 27-Jul 10;102(26-27):1972-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Increasing number of skin cancer cases--also among the younger].
  • The incidence of skin cancer has been increasing for several years.
  • This is the case in malignant melanoma as well as in squamous cell carcinoma and basal cell carcinoma.
  • Skin cancer is most common among the elderly, but is now also more frequently found in younger people.
  • Surgery is often the treatment of choice and this is still the case in malignant melanoma and most cases of squamous cell carcinoma.
  • For basal cell carcinoma, Bowen's disease and actinic keratoses, however, alternative treatments should be considered.
  • Today, dermatologists can offer patients with skin cancer several new treatments besides surgery.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Melanoma / epidemiology. Skin Neoplasms / epidemiology
  • [MeSH-minor] Adult. Age Factors. Aged. Bowen's Disease / epidemiology. Bowen's Disease / therapy. Humans. Incidence. Prognosis. Sweden / epidemiology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16044750.001).
  • [ISSN] 0023-7205
  • [Journal-full-title] Läkartidningen
  • [ISO-abbreviation] Lakartidningen
  • [Language] swe
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Sweden
  • [Number-of-references] 20
  •  go-up   go-down


63. Zamanian A, Mahjub H, Mehralian A: Skin diseases in kidney transplant recipients. Urol J; 2006;3(4):230-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin diseases in kidney transplant recipients.
  • INTRODUCTION: The aim of this study was to evaluate the frequency of skin diseases in kidney transplant recipients.
  • The patients were examined by a dermatologist and diagnosis was made on the basis of clinical observations.
  • RESULTS: Of the patients, 226 (97%) suffered from one or more skin lesions.
  • Also, infectious and premalignant or malignant lesions (actinic keratosis, squamous cell carcinoma, and basal cell carcinoma) were seen in 48.9% and 14.2% of the patients.
  • The mean duration of immunosuppressive therapy was significantly higher in patients with infectious skin diseases (P < .001).
  • CONCLUSION: Skin lesions are a significant problem in kidney transplant recipients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17559047.001).
  • [ISSN] 1735-1308
  • [Journal-full-title] Urology journal
  • [ISO-abbreviation] Urol J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  •  go-up   go-down


64. Nagpal S, Na S, Rathnachalam R: Noncalcemic actions of vitamin D receptor ligands. Endocr Rev; 2005 Aug;26(5):662-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Physiological and pharmacological actions of 1,25-(OH)(2)D(3) in various systems, along with the detection of VDR in target cells, have indicated potential therapeutic applications of VDR ligands in inflammation (rheumatoid arthritis, psoriatic arthritis), dermatological indications (psoriasis, actinic keratosis, seborrheic dermatitis, photoaging), osteoporosis (postmenopausal and steroid-induced osteoporosis), cancers (prostate, colon, breast, myelodysplasia, leukemia, head and neck squamous cell carcinoma, and basal cell carcinoma), secondary hyperparathyroidism, and autoimmune diseases (systemic lupus erythematosus, type I diabetes, multiple sclerosis, and organ transplantation).
  • Furthermore, encouraging results have been obtained with VDR ligands in clinical trials of prostate cancer and hepatocellular carcinoma.

  • MedlinePlus Health Information. consumer health - Vitamin D.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15798098.001).
  • [ISSN] 0163-769X
  • [Journal-full-title] Endocrine reviews
  • [ISO-abbreviation] Endocr. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ligands; 0 / Receptors, Calcitriol; 1406-16-2 / Vitamin D
  • [Number-of-references] 284
  •  go-up   go-down


65. Nindl I, Gottschling M, Stockfleth E: Human papillomaviruses and non-melanoma skin cancer: basic virology and clinical manifestations. Dis Markers; 2007;23(4):247-59
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomaviruses and non-melanoma skin cancer: basic virology and clinical manifestations.
  • Human papillomaviruses (HPV) infect cutaneous and mucosal epithelia and induce benign and malignant lesions.
  • Non-melanoma skin cancer (NMSC), encompassing basal cell carcinoma and squamous cell carcinoma (SCC), is the most frequent cancer in the Caucasian population, and the incidence has increased dramatically worldwide.
  • HPV types detected in skin tumours of these patients are referred to as EV/cutaneous HPV types belonging to the beta- and gamma-papillomaviruses (PV).
  • [MeSH-major] Papillomaviridae / pathogenicity. Papillomavirus Infections / complications. Skin Neoplasms / etiology
  • [MeSH-minor] Animals. Carcinoma, Basal Cell / etiology. Carcinoma, Basal Cell / virology. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / virology. Disease Models, Animal. Epidermodysplasia Verruciformis / complications. Epidermodysplasia Verruciformis / virology. Humans. Immune Tolerance. Risk Factors. Transplantation Immunology. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17627060.001).
  • [ISSN] 0278-0240
  • [Journal-full-title] Disease markers
  • [ISO-abbreviation] Dis. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 155
  • [Other-IDs] NLM/ PMC3851066
  •  go-up   go-down


66. Bugatti L, Filosa G: Dermatoscopic features of cutaneous atypical fibroxanthoma: three cases. Clin Exp Dermatol; 2009 Dec;34(8):e898-900
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Atypical fibroxanthoma (AFX) is an uncommon, low-grade, malignant, spindle-cell tumour of fibrohistiocytic histogenesis, which can mimic other malignant skin tumours, such as basal and squamous cell carcinoma (CC), melanoma, and Merkel cell carcinoma (MCC).
  • AFX may be added to the list of slightly pigmented, reddish, malignant cutaneous tumours, such as SCC, MCC, amelanotic/hypomelanotic melanoma and eccrine porocarcinoma, which display prominent and chaotic dermatoscopic neoangiogenetic features in more advanced stages of proliferation.
  • [MeSH-major] Dermoscopy / methods. Histiocytoma, Benign Fibrous / pathology. Melanoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20055861.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


67. Euvrard S: [Skin cancers after organ transplants]. Presse Med; 2008 Oct;37(10):1475-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Skin cancers after organ transplants].
  • Squamous cell carcinoma and basal cell carcinoma are the most common cancers after transplants, affecting more than half of all patients in the long term.
  • In the 5 years after a first squamous cell carcinoma, 90 to 100% of transplant patients subsequently develop multiple skin carcinomas of various types and at least 20% develop noncutaneous cancers.
  • Management of these patients requires, beyond the usual dermatologic treatments, a revision of their immunosuppression regimen to reduce the tumor risk.
  • New immunosuppressants that inhibit the m-TOR protein (sirolimus and everolimus) appear to offer promising perspectives, and patients treated with these drugs from the time of their transplantation have fewer skin cancers than patients with the standard protocols.
  • Several prospective French multicenter studies are currently assessing the effect of replacing anticalcineurins by sirolimus or everolimus for secondary prevention of skin cancers in renal or cardiac transplant patients who have already developed skin cancer.
  • [MeSH-major] Organ Transplantation / adverse effects. Skin Neoplasms / etiology
  • [MeSH-minor] Herpesviridae Infections / complications. Herpesviridae Infections / diagnosis. Humans. Immunocompromised Host. Risk Factors. Xeroderma Pigmentosum / diagnosis. Xeroderma Pigmentosum / epidemiology. Xeroderma Pigmentosum / virology

  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18775633.001).
  • [ISSN] 2213-0276
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 12
  •  go-up   go-down


68. Zhao B, He YY: Recent advances in the prevention and treatment of skin cancer using photodynamic therapy. Expert Rev Anticancer Ther; 2010 Nov;10(11):1797-809
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in the prevention and treatment of skin cancer using photodynamic therapy.
  • Recently, PDT has been widely used in treating non-melanoma skin malignancies, the most common cancer in the USA, with superior cosmetic outcomes compared with conventional therapies.
  • After treatment with ALA or methyl 5-aminolevulinate, protoporphyrin IX preferentially accumulates in the lesion area of various skin diseases, which allows not only PDT treatment but also fluorescence diagnosis with ALA-induced porphyrins.
  • Susceptible lesions include various forms of non-melanoma skin cancer such as actinic keratosis, basal cell carcinoma and squamous cell carcinoma.
  • This article summarizes the main principles of PDT and its current clinical use in the management of non-melanoma skin cancers, as well as recent developments and possible future research directions.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Photodermatol Photoimmunol Photomed. 2006 Oct;22(5):254-8 [16948827.001]
  • [Cites] Acta Derm Venereol. 2006;86(5):418-21 [16955186.001]
  • [Cites] Br J Dermatol. 2006 Nov;155(5):1029-36 [17034536.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2006 Nov-Dec;22(6):498-9 [17117119.001]
  • [Cites] Dermatol Clin. 2007 Jan;25(1):5-14 [17126737.001]
  • [Cites] Dermatol Clin. 2007 Jan;25(1):89-94 [17126746.001]
  • [Cites] Dermatol Clin. 2007 Jan;25(1):95-100 [17126747.001]
  • [Cites] Br J Dermatol. 2007 Feb;156(2):320-8 [17223873.001]
  • [Cites] Arch Dermatol. 2007 Feb;143(2):264-5 [17310011.001]
  • [Cites] Expert Opin Drug Deliv. 2007 Mar;4(2):131-48 [17335411.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2007 Apr;21(4):439-51 [17373968.001]
  • [Cites] Br J Dermatol. 2007 May;156(5):793-801 [17419691.001]
  • [Cites] Br J Dermatol. 2007 Jul;157(1):87-91 [17501954.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Aug;4(8):462-9 [17657251.001]
  • [Cites] Arch Dermatol. 2007 Sep;143(9):1131-6 [17875873.001]
  • [Cites] Photomed Laser Surg. 2007 Oct;25(5):428-35 [17975957.001]
  • [Cites] Clin Transl Oncol. 2008 Mar;10(3):148-54 [18321817.001]
  • [Cites] Br J Dermatol. 2008 May;158(5):994-9 [18341663.001]
  • [Cites] Br J Pharmacol. 2008 May;154(1):1-3 [18362894.001]
  • [Cites] J Am Chem Soc. 2008 Aug 13;130(32):10643-7 [18642918.001]
  • [Cites] Eur J Dermatol. 2008 Sep-Oct;18(5):547-53 [18693158.001]
  • [Cites] Trends Biotechnol. 2008 Nov;26(11):612-21 [18804298.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Dec 14;60(15):1627-37 [18930086.001]
  • [Cites] Br J Dermatol. 2008 Dec;159(6):1245-66 [18945319.001]
  • [Cites] Exp Dermatol. 2009 Feb;18(2):116-21 [18643849.001]
  • [Cites] Chem Commun (Camb). 2009 Mar 28;(12):1475-7 [19277361.001]
  • [Cites] Photodiagnosis Photodyn Ther. 2008 Jun;5(2):127-33 [19356643.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2009 May;23(5):505-16 [19175703.001]
  • [Cites] Br J Dermatol. 2009 Jun;160(6):1308-14 [19416257.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2009 Jul;29(7):992-1000 [19057023.001]
  • [Cites] Nat Med. 2009 Jul;15(7):713 [19584845.001]
  • [Cites] Toxicol Appl Pharmacol. 2009 Dec 1;241(2):163-72 [19695274.001]
  • [Cites] J Pathol. 2009 Dec;219(4):400-9 [19771562.001]
  • [Cites] Immunol Res. 2010 Mar;46(1-3):216-26 [19763892.001]
  • [Cites] Arch Dermatol. 2010 Mar;146(3):283-7 [20231499.001]
  • [Cites] Eur J Dermatol. 2000 Oct-Nov;10(7):568-75; discussion 576 [11056436.001]
  • [Cites] Ophthalmology. 2000 Dec;107(12):2314-7 [11186878.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2000 Jul;14(4):298-300 [11204521.001]
  • [Cites] Aliment Pharmacol Ther. 2001 Mar;15(3):311-21 [11207506.001]
  • [Cites] Br J Dermatol. 2001 Apr;144(4):832-40 [11298545.001]
  • [Cites] Br J Dermatol. 2001 Jun;144(6):1207-14 [11422043.001]
  • [Cites] Br J Dermatol. 2001 Sep;145(3):467-71 [11531838.001]
  • [Cites] J Photochem Photobiol B. 2001 Sep 15;62(3):140-5 [11566277.001]
  • [Cites] Photochem Photobiol. 2001 Nov;74(5):656-69 [11723793.001]
  • [Cites] J Chemother. 2001 Oct;13(5):494-502 [11760213.001]
  • [Cites] J Photochem Photobiol B. 2002 Mar;66(2):89-106 [11897509.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2005 Jun;21(3):142-9 [15888131.001]
  • [Cites] J Photochem Photobiol B. 2005 Jun 1;79(3):231-41 [15896650.001]
  • [Cites] Australas J Dermatol. 2005 Aug;46(3):196-8 [16008656.001]
  • [Cites] Br J Dermatol. 2005 Sep;153(3):672-4 [16120168.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Dec;56(6):569-77 [16001166.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Oct;5(5):791-800 [16221049.001]
  • [Cites] J Am Acad Dermatol. 2005 Nov;53(5 Suppl 1):S273-6 [16227107.001]
  • [Cites] Br J Dermatol. 2006 Jan;154(1):146-9 [16403108.001]
  • [Cites] J Invest Dermatol. 2006 Mar;126(3):569-74 [16374480.001]
  • [Cites] J Invest Dermatol. 2006 Mar;126(3):542-4 [16482195.001]
  • [Cites] J Am Acad Dermatol. 2006 Mar;54(3):524-6 [16488310.001]
  • [Cites] Br J Dermatol. 2002 Apr;146(4):552-67 [11966684.001]
  • [Cites] Optom Vis Sci. 2002 Apr;79(4):218-24 [11999147.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3956-61 [12124326.001]
  • [Cites] Lasers Med Sci. 2002;17(3):173-86 [12181632.001]
  • [Cites] Clin Exp Dermatol. 2002 Sep;27(6):516-8 [12372098.001]
  • [Cites] Methods Mol Med. 2003;75:507-26 [12407761.001]
  • [Cites] J Photochem Photobiol B. 2003 Feb;69(2):121-7 [12633984.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1681-91 [12711744.001]
  • [Cites] J Am Chem Soc. 2003 Jul 2;125(26):7860-5 [12823004.001]
  • [Cites] Mol Immunol. 2003 Jul;39(17-18):1133-6 [12835091.001]
  • [Cites] J Dermatolog Treat. 2003;14 Suppl 3:23-6 [14522638.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3591-600 [14666654.001]
  • [Cites] Br J Dermatol. 2003 Dec;149(6):1242-9 [14674903.001]
  • [Cites] Dermatol Surg. 2004 Jan;30(1):63-6 [14692930.001]
  • [Cites] Transplantation. 2004 Jan 15;77(1):115-21 [14724445.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):41-6 [14732659.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):116-20 [14732670.001]
  • [Cites] J Am Acad Dermatol. 2004 Mar;50(3):363-7 [14988676.001]
  • [Cites] Br J Dermatol. 2004 Feb;150(2):337-40 [14996106.001]
  • [Cites] Int J Cancer. 2004 Jun 10;110(2):295-300 [15069697.001]
  • [Cites] Br J Dermatol. 2004 Jun;150(6):1061-9 [15214890.001]
  • [Cites] Australas J Dermatol. 2004 Aug;45(3):172-4 [15250896.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):196-200 [15270891.001]
  • [Cites] Curr Pharm Biotechnol. 2004 Aug;5(4):397-408 [15320770.001]
  • [Cites] Br J Dermatol. 2004 Aug;151(2):472-80 [15327557.001]
  • [Cites] Onkologie. 2004 Aug;27(4):407-11 [15347900.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 May;130(5):279-84 [14997383.001]
  • [Cites] Lancet. 1988 Apr 9;1(8589):795-7 [2895318.001]
  • [Cites] J Photochem Photobiol B. 1990 Jun;6(1-2):143-8 [2121931.001]
  • [Cites] Aust N Z J Surg. 1991 May;61(5):340-8 [2025186.001]
  • [Cites] Photochem Photobiol. 1991 Nov;54(5):659 [1798741.001]
  • [Cites] Photochem Photobiol. 1992 Jun;55(6):931-48 [1409894.001]
  • [Cites] Arch Dermatol Res. 1995;287(7):665-74 [8534131.001]
  • [Cites] J Urol. 1996 Jan;155(1):105-9; discussion 109-10 [7490803.001]
  • [Cites] Photochem Photobiol. 1996 Jun;63(6):892-7 [8992510.001]
  • [Cites] Dermatology. 1996;192(3):246-51 [8726640.001]
  • [Cites] J Photochem Photobiol B. 1996 Nov;36(2):169-74 [9002254.001]
  • [Cites] J Photochem Photobiol B. 1996 Nov;36(2):199-204 [9002261.001]
  • [Cites] Cancer. 1997 Jun 15;79(12):2282-308 [9191516.001]
  • [Cites] Arch Dermatol. 1997 Jun;133(6):727-32 [9197826.001]
  • [Cites] Photochem Photobiol. 1997 Oct;66(4):493-6 [9337620.001]
  • [Cites] Aesthetic Plast Surg. 1997 Nov-Dec;21(6):437-9 [9354609.001]
  • [Cites] Arch Dermatol. 1998 Feb;134(2):207-14 [9487213.001]
  • [Cites] J Invest Dermatol. 1998 May;110(5):746-51 [9579539.001]
  • [Cites] Australas J Dermatol. 1998 May;39(2):63-8; quiz 69-70 [9611372.001]
  • [Cites] J Clin Laser Med Surg. 1996 Oct;14(5):219-21 [9612186.001]
  • [Cites] Acta Derm Venereol. 1999 Jan;79(1):54-61 [10086861.001]
  • [Cites] Br J Dermatol. 1999 Mar;140(3):514-7 [10233277.001]
  • [Cites] J Invest Dermatol. 1959 Feb;32(2, Part 2):229-31 [13641790.001]
  • [Cites] Angew Chem Int Ed Engl. 2005 Jan 7;44(3):419-23 [15624158.001]
  • [Cites] Gastrointest Endosc. 2005 Jan;61(1):13-8 [15672050.001]
  • [Cites] Breast. 2005 Feb;14(1):65-7 [15695084.001]
  • [Cites] Br J Dermatol. 2005 Apr;152(4):765-72 [15840111.001]
  • [Cites] Br J Dermatol. 2000 Feb;142(2):338-9 [10730770.001]
  • [Cites] Br J Dermatol. 2000 Apr;142(4):825-6 [10792247.001]
  • [Cites] Cancer. 2000 May 15;88(10):2275-82 [10820349.001]
  • [Cites] J Invest Dermatol. 2000 Sep;115(3):396-401 [10951274.001]
  • [Cites] J Urol. 2006 Apr;175(4):1201-7 [16515960.001]
  • [Cites] Br J Dermatol. 2006 Apr;154(4):747-50 [16536822.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 2006;25(1-2):441-51 [16566734.001]
  • [Cites] Acta Derm Venereol. 2006;86(1):25-8 [16585985.001]
  • [Cites] Clin Exp Pharmacol Physiol. 2006 May-Jun;33(5-6):551-6 [16700893.001]
  • [Cites] Int J Dermatol. 2006 May;45(5):489-98 [16700779.001]
  • [Cites] Arch Dermatol. 2006 Jun;142(6):729-35 [16785375.001]
  • (PMID = 21080805.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / R01 ES016936-01A2; United States / NCI NIH HHS / CA / P30 CA014599; United States / NIEHS NIH HHS / ES / R01 ES016936; United States / Intramural NIH HHS / / ZIA ES050117-21; United States / NIEHS NIH HHS / ES / ES016936-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS263919; NLM/ PMC3030451
  •  go-up   go-down


69. Mancuso M, Gallo D, Saran A: Re: Modulation of basal and squamous cell carcinoma by endogenous estrogen in mouse models of skin cancer. Carcinogenesis; 2009 Apr;30(4):721
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Re: Modulation of basal and squamous cell carcinoma by endogenous estrogen in mouse models of skin cancer.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Disease Models, Animal. Estrogens / pharmacology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Carcinogenesis. 2009 Apr;30(4):720 [19168587.001]
  • (PMID = 19168582.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Estrogens
  •  go-up   go-down


70. Chan S, Dhadda AS, Swindell R: Single fraction radiotherapy for small superficial carcinoma of the skin. Clin Oncol (R Coll Radiol); 2007 May;19(4):256-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single fraction radiotherapy for small superficial carcinoma of the skin.
  • AIMS: To define the optimal dose and maximum tumour size of basal and squamous cell carcinoma of skin that can be treated by single fraction radiotherapy.
  • MATERIALS AND METHODS: A review was undertaken of 1005 lesions of basal/squamous cell carcinoma of the skin involving 806 patients treated at a single centre with 10 years of follow-up.
  • RESULTS: The overall disease-free and necrosis-free rates at 5 years were 90% and 84%, respectively.
  • The crude 10-year recurrence rate was 4% (95% CI 3.4-5.4%), with late skin necrosis at 6% (95% CI 4.8-7.2%).
  • There was no difference in tumour recurrence rates between 20 and 22.5 Gy (P=0.3), but there was a significantly higher skin necrosis rate at the treated site in the patients who had received 22.5 Gy (P=0.003).
  • Most skin necrosis healed spontaneously, with only 16% requiring surgical intervention.
  • CONCLUSIONS: Single fraction radiotherapy is an acceptable treatment for small superficial BCC and SCC of the head and neck region in patients who have difficulty attending multiple hospital visits as long as the field size required for treatment is no larger than 3 cm in diameter.
  • [MeSH-major] Head and Neck Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Skin Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / mortality. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / radiotherapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Disease-Free Survival. England / epidemiology. Female. Humans. Male. Medical Records. Middle Aged. Necrosis / pathology. Radiation Dosage. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17379488.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


71. Hong H, Sun J, Cai W: Anatomical and molecular imaging of skin cancer. Clin Cosmet Investig Dermatol; 2008;1:1-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anatomical and molecular imaging of skin cancer.
  • Skin cancer is the most common form of cancer types.
  • It is generally divided into two categories: melanoma (∼ 5%) and nonmelanoma (∼ 95%), which can be further categorized into basal cell carcinoma, squamous cell carcinoma, and some rare skin cancer types.
  • Biopsy is still the gold standard for skin cancer evaluation in the clinic.
  • Various anatomical imaging techniques have been used to evaluate different types of skin cancer lesions, including laser scanning confocal microscopy, optical coherence tomography, high-frequency ultrasound, terahertz pulsed imaging, magnetic resonance imaging, and some other recently developed techniques such as photoacoustic microscopy.
  • However, anatomical imaging alone may not be sufficient in guiding skin cancer diagnosis and therapy.
  • Over the last decade, various molecular imaging techniques (in particular single photon emission computed tomography and positron emission tomography) have been investigated for skin cancer imaging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Z Arztl Fortbild Qualitatssich. 1997 Jul;91(4):347-53 [9340205.001]
  • [Cites] Radiographics. 1997 Nov-Dec;17(6):1559-65 [9397463.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1770-6 [9586890.001]
  • [Cites] NMR Biomed. 2008 Mar;21(3):296-300 [18246539.001]
  • [Cites] J Biomed Opt. 2008 Jan-Feb;13(1):014003 [18315361.001]
  • [Cites] Adv Exp Med Biol. 2008;624:215-26 [18348459.001]
  • [Cites] Adv Exp Med Biol. 2008;624:227-40 [18348460.001]
  • [Cites] Adv Exp Med Biol. 2008;624:296-318 [18348465.001]
  • [Cites] J Biomed Opt. 2008 Mar-Apr;13(2):024013 [18465976.001]
  • [Cites] J Nucl Med. 2008 Jun;49 Suppl 2:113S-28S [18523069.001]
  • [Cites] Opt Express. 2002 Jul 29;10(15):707-13 [19451924.001]
  • [Cites] Biotechniques. 2005 Dec;39(6 Suppl):S6-13 [20158503.001]
  • [Cites] J Nucl Med. 1990 Nov;31(11):1831-5 [2230996.001]
  • [Cites] Ann Surg. 1986 Sep;204(3):223-35 [3753057.001]
  • [Cites] Science. 1994 Apr 22;264(5158):569-71 [7512751.001]
  • [Cites] Annu Rev Cell Dev Biol. 1996;12:697-715 [8970741.001]
  • [Cites] Dermatol Surg. 1997 Jan;23(1):43-5 [9107293.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):12814-8 [9788997.001]
  • [Cites] Am J Pathol. 1998 Nov;153(5):1347-51 [9811323.001]
  • [Cites] AJR Am J Roentgenol. 1999 Feb;172(2):457-61 [9930803.001]
  • [Cites] Nucl Med Biol. 1999 Aug;26(6):687-93 [10587108.001]
  • [Cites] Crit Rev Oncog. 2000;11(2):147-63 [11005510.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5649-58 [11059756.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4474-82 [11389078.001]
  • [Cites] Nucl Med Biol. 2001 Jul;28(5):493-8 [11516693.001]
  • [Cites] J Nucl Med. 2001 Dec;42(12):1847-55 [11752084.001]
  • [Cites] Nucl Med Biol. 2006 Aug;33(6):723-33 [16934691.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):913-21 [17146742.001]
  • [Cites] Br J Dermatol. 2007 Jan;156(1):81-4 [17199571.001]
  • [Cites] J Nucl Med. 2007 Jan;48(1):64-72 [17204700.001]
  • [Cites] J Nucl Med. 2007 Jan;48(1):73-80 [17204701.001]
  • [Cites] Cancer Imaging. 2006;6:204-8 [17208677.001]
  • [Cites] Bull Cancer. 2007 Jan;94(1):93-8 [17237009.001]
  • [Cites] J Nucl Med. 2007 Feb;48(2):304-10 [17268029.001]
  • [Cites] J Nucl Med. 2007 Mar;48(3):429-36 [17332621.001]
  • [Cites] Bioconjug Chem. 2007 May-Jun;18(3):765-72 [17348700.001]
  • [Cites] Dermatol Surg. 2007 Apr;33(4):421-5; discussion 425-6 [17430375.001]
  • [Cites] Front Biosci. 2007;12:4514-24 [17485393.001]
  • [Cites] Rofo. 2007 Jun;179(6):618-26 [17492539.001]
  • [Cites] Nucl Med Biol. 2007 May;34(4):363-70 [17499725.001]
  • [Cites] J Nucl Med. 2007 Jun;48(6):987-94 [17504880.001]
  • [Cites] Surg Oncol Clin N Am. 2007 Apr;16(2):403-30 [17560520.001]
  • [Cites] J Am Acad Dermatol. 2007 Oct;57(4):629-37 [17610989.001]
  • [Cites] J Biomed Opt. 2007 May-Jun;12(3):034027 [17614735.001]
  • [Cites] Arch Dermatol. 2007 Jul;143(7):883-6 [17638732.001]
  • [Cites] Cancer Biother Radiopharm. 2007 Jun;22(3):333-41 [17651039.001]
  • [Cites] Cutis. 2007 Mar;79(3):241-8 [17674590.001]
  • [Cites] Dermatol Surg. 2007 Oct;33(10):1158-74 [17903149.001]
  • [Cites] Dermatol Surg. 2007 Oct;33(10):1220-7; discussion 1226-7 [17903155.001]
  • [Cites] J Radiol. 1998 Apr;79(4):313-7 [9757255.001]
  • [Cites] Eur J Nucl Med. 1998 Oct;25(10):1383-9 [9818277.001]
  • [Cites] Bioconjug Chem. 2006 May-Jun;17(3):662-9 [16704203.001]
  • [Cites] J Dermatol Sci. 2006 Aug;43(2):135-41 [16806842.001]
  • [Cites] J Am Acad Dermatol. 2006 Sep;55(3):408-12 [16908344.001]
  • [Cites] J Nucl Med. 1999 Apr;40(4):591-603 [10210218.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2917-23 [10383155.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;44(4):343-8 [10447583.001]
  • [Cites] J Nucl Med. 1999 Jun;40(6):1061-71 [10452325.001]
  • [Cites] J Am Acad Dermatol. 2000 Jul;43(1 Pt 1):42-8 [10863222.001]
  • [Cites] Neoplasia. 2000 Jan-Apr;2(1-2):9-25 [10933065.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1781-5 [11280722.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2674-8 [11352959.001]
  • [Cites] J Nucl Med. 2001 May;42(5 Suppl):1S-93S [11483694.001]
  • [Cites] Science. 2001 Oct 12;294(5541):339-45 [11546839.001]
  • [Cites] Hybrid Hybridomics. 2001;20(5-6):351-60 [11839253.001]
  • [Cites] Genes Dev. 2003 Mar 1;17(5):545-80 [12629038.001]
  • [Cites] Nat Rev Cancer. 2002 Feb;2(2):91-100 [12635172.001]
  • [Cites] Pigment Cell Res. 2003 Jun;16(3):266-72 [12753400.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3172-9 [12789293.001]
  • [Cites] Lab Invest. 2003 Sep;83(9):1279-83 [13679435.001]
  • [Cites] Nat Biotechnol. 2003 Nov;21(11):1361-7 [14595364.001]
  • [Cites] Bioconjug Chem. 2003 Nov-Dec;14(6):1177-84 [14624632.001]
  • [Cites] Bioconjug Chem. 2004 Jan-Feb;15(1):61-9 [14733584.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1411-8 [14973076.001]
  • [Cites] Magn Reson Imaging. 2004 Jul;22(6):843-50 [15234453.001]
  • [Cites] Mod Pathol. 2005 Apr;18(4):469-74 [15529179.001]
  • [Cites] J Nucl Med. 2005 Jan;46(1):121-9 [15632042.001]
  • [Cites] Skin Res Technol. 2007 Nov;13(4):463-71 [17908200.001]
  • [Cites] Dermatology. 2007;215(4):365-72 [17912001.001]
  • [Cites] Panminerva Med. 2007 Sep;49(3):119-38 [17912148.001]
  • [Cites] Nucl Med Biol. 2007 Nov;34(8):945-53 [17998097.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Dec;7(12):1707-16 [18062745.001]
  • [Cites] Int J Pharm. 2008 Apr 2;353(1-2):233-42 [18191509.001]
  • [Cites] Bioconjug Chem. 2008 Feb;19(2):539-47 [18197608.001]
  • [Cites] Skin Res Technol. 2008 Feb;14(1):18-25 [18211598.001]
  • [Cites] Skin Res Technol. 2008 Feb;14(1):89-92 [18211606.001]
  • [Cites] Br J Dermatol. 2008 Feb;158(2):329-33 [18215250.001]
  • [Cites] Dermatol Surg. 2008 May;34(5):610-9 [18261097.001]
  • [Cites] Anal Sci. 2008 Feb;24(2):185-92 [18270407.001]
  • [Cites] Curr Opin Oncol. 2008 Mar;20(2):196-200 [18300770.001]
  • [Cites] Int J Cosmet Sci. 2008 Feb;30(1):1-17 [18377626.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2008 May;22(5):606-15 [18410618.001]
  • [Cites] J Nucl Med. 2008 May;49(5):823-9 [18413404.001]
  • [Cites] Clin Nucl Med. 2008 May;33(5):353-5 [18431156.001]
  • [Cites] J Nucl Med. 2008 Jun;49(6):879-86 [18483090.001]
  • [Cites] Semin Cutan Med Surg. 2008 Mar;27(1):37-43 [18486023.001]
  • [Cites] AJR Am J Roentgenol. 2008 Jul;191(1):285-9 [18562760.001]
  • [Cites] Cancer Res. 1990 Feb 1;50(3 Suppl):904s-908s [2297740.001]
  • [Cites] Cancer Res. 1990 Feb 1;50(3 Suppl):941s-948s [2297746.001]
  • [Cites] Cancer Res. 1990 Jun 1;50(11):3445-52 [2334941.001]
  • [Cites] Neoplasma. 1989;36(5):505-11 [2812147.001]
  • [Cites] J Nucl Med. 1988 Mar;29(3):329-37 [3346743.001]
  • [Cites] Biomed Pharmacother. 1986;40(10):392-8 [3580508.001]
  • [Cites] Cancer Immunol Immunother. 1987;24(3):221-4 [3594484.001]
  • [Cites] NCI Monogr. 1987;(3):3-9 [3821916.001]
  • [Cites] Radiology. 1985 May;155(2):487-92 [3983400.001]
  • [Cites] Cancer Res. 1985 Jul;45(7):3378-87 [4005860.001]
  • [Cites] Br J Urol. 1994 Oct;74(4):521-2 [7820438.001]
  • [Cites] Arch Dermatol. 1995 Mar;131(3):279-85 [7887656.001]
  • [Cites] Int J Cancer. 1994 Sep 1;58(5):749-55 [8077062.001]
  • [Cites] Melanoma Res. 1993 Dec;3(6):395-401 [8161879.001]
  • [Cites] Br J Dermatol. 1993 May;128(5):525-32 [8504043.001]
  • [Cites] Clin Nucl Med. 1997 Jan;22(1):25-9 [8993869.001]
  • [Cites] Nucl Med Biol. 1997 Feb;24(2):171-8 [9089709.001]
  • [Cites] Bioconjug Chem. 1997 May-Jun;8(3):347-53 [9177840.001]
  • [Cites] Magn Reson Med. 2005 Mar;53(3):621-7 [15723405.001]
  • [Cites] PLoS Med. 2005 Mar;2(3):e70 [15783258.001]
  • [Cites] Mol Imaging. 2004 Oct;3(4):343-51 [15802051.001]
  • [Cites] J Med Chem. 2005 Apr 21;48(8):2985-92 [15828837.001]
  • [Cites] J Nucl Med. 2005 Aug;46(8):1333-41 [16085591.001]
  • [Cites] Nat Med. 2005 Nov;11(11):1250-5 [16258537.001]
  • [Cites] Mod Pathol. 2006 Feb;19 Suppl 2:S127-47 [16446711.001]
  • [Cites] J Am Acad Dermatol. 2006 Apr;54(4):638-43 [16546585.001]
  • [Cites] J Nucl Med. 2006 May;47(5):763-9 [16644745.001]
  • [Cites] J Nucl Med. 2006 Jun;47(6):957-67 [16741305.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3942-9 [16818691.001]
  • [Cites] Nat Biotechnol. 2006 Jul;24(7):848-51 [16823374.001]
  • [Cites] J Nucl Med. 2006 Sep;47(9):1434-9 [16954550.001]
  • [Cites] Mol Cancer Ther. 2006 Nov;5(11):2624-33 [17121909.001]
  • [Cites] J Dermatol Sci. 2007 Mar;45(3):167-73 [17215110.001]
  • [Cites] Conf Proc IEEE Eng Med Biol Soc. 2005;1:190-2 [17282143.001]
  • [Cites] Melanoma Res. 2007 Apr;17(2):117-27 [17496787.001]
  • [Cites] Tech Vasc Interv Radiol. 2006 Sep;9(3):125-32 [17561215.001]
  • [Cites] Arch Dermatol. 2007 Jun;143(6):727-34 [17576938.001]
  • [Cites] J Dtsch Dermatol Ges. 2007 Aug;5(8):689-707 [17659044.001]
  • [Cites] Int J Dermatol. 2007 Sep;46(9):895-904 [17822489.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):186-208 [17846765.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17489-93 [17954911.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Nov;7(11):1633-42 [18020929.001]
  • [Cites] Br J Dermatol. 2007 Dec;157 Suppl 2:56-8 [18067634.001]
  • [Cites] Mol Cancer Ther. 2008 Jan;7(1):101-9 [18202013.001]
  • [Cites] Cancer. 2002 Feb 15;94(4 Suppl):1196-201 [11877745.001]
  • [Cites] Phys Med Biol. 2002 Apr 7;47(7):R67-84 [11996068.001]
  • [Cites] J Med Chem. 2002 Jul 4;45(14):3048-56 [12086490.001]
  • [Cites] Ann Surg Oncol. 2002 Aug;9(7):646-53 [12167578.001]
  • [Cites] Phys Med Biol. 2002 Nov 7;47(21):3847-52 [12452576.001]
  • [Cites] J Nucl Med. 2002 Dec;43(12):1699-706 [12468522.001]
  • [Cites] J Invest Dermatol. 2003 Jan;120(1):72-8 [12535200.001]
  • [Cites] J Nucl Med. 2003 Aug;44(8):1210-8 [12902409.001]
  • [Cites] Cancer Res. 1992 May 1;52(9):2545-8 [1314697.001]
  • [Cites] Science. 1992 Aug 28;257(5074):1248-51 [1325670.001]
  • [Cites] Br J Dermatol. 2003 Nov;149(5):1035-40 [14632811.001]
  • [Cites] Optometry. 2003 Dec;74(12):760-4 [14677727.001]
  • [Cites] Klin Monbl Augenheilkd. 2003 Dec;220(12):822-9 [14704937.001]
  • [Cites] J Nucl Med. 2004 Jan;45(1):116-23 [14734683.001]
  • [Cites] Nuklearmedizin. 2004 Feb;43(1):26-32 [14978538.001]
  • [Cites] Br J Dermatol. 2004 Apr;150(4):677-86 [15099363.001]
  • [Cites] Ann Surg Oncol. 2004 Aug;11(8):731-8 [15249335.001]
  • [Cites] J Nucl Med. 2004 Aug;45(8):1323-7 [15299056.001]
  • [Cites] J Invest Dermatol. 2004 Sep;123(3):458-63 [15304083.001]
  • [Cites] Br J Dermatol. 2004 Aug;151(2):424-32 [15327550.001]
  • [Cites] Cancer J. 2004 Jul-Aug;10(4):262-70 [15383207.001]
  • [Cites] Vestn Rentgenol Radiol. 2004 Mar-Apr;(2):44-54 [15458273.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2004 Dec;20(6):283-8 [15533235.001]
  • [Cites] Phys Med Biol. 2004 Nov 7;49(21):N363-9 [15584535.001]
  • [Cites] Arch Dermatol. 2005 Feb;141(2):217-24 [15724019.001]
  • [Cites] Arch Dermatol. 2005 Feb;141(2):269-70 [15724029.001]
  • [Cites] Curr Opin Oncol. 2005 Mar;17(2):154-9 [15725921.001]
  • [Cites] J Nucl Med. 2005 May;46(5):887-95 [15872364.001]
  • [Cites] Curr Opin Oncol. 1992 Apr;4(2):380-5 [1591311.001]
  • [Cites] Nucl Med Biol. 2005 Jul;32(5):485-93 [15982579.001]
  • [Cites] Cancer Metastasis Rev. 2005 Jun;24(2):195-222 [15986132.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5616-21 [16061880.001]
  • [Cites] J Dermatol Sci. 2005 Nov;40(2):85-94 [16139481.001]
  • [Cites] Radiology. 1992 Aug;184(2):427-34 [1620841.001]
  • [Cites] J Biomed Opt. 2005 Sep-Oct;10(5):054010 [16292970.001]
  • [Cites] J Am Acad Dermatol. 2005 Dec;53(6):979-85 [16310058.001]
  • [Cites] Arch Dermatol. 2006 Mar;142(3):393; author reply 393 [16549724.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):193-200 [16615102.001]
  • (PMID = 21437135.001).
  • [ISSN] 1178-7015
  • [Journal-full-title] Clinical, cosmetic and investigational dermatology
  • [ISO-abbreviation] Clin Cosmet Investig Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3048596
  • [Keywords] NOTNLM ; anatomical imaging / antibody / melanoma / molecular imaging / positron emission tomography / skin cancer
  •  go-up   go-down


72. Baron ED, Malbasa CL, Santo-Domingo D, Fu P, Miller JD, Hanneman KK, Hsia AH, Oleinick NL, Colussi VC, Cooper KD: Silicon phthalocyanine (Pc 4) photodynamic therapy is a safe modality for cutaneous neoplasms: results of a phase 1 clinical trial. Lasers Surg Med; 2010 Dec;42(10):728-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Silicon phthalocyanine (Pc 4) photodynamic therapy is a safe modality for cutaneous neoplasms: results of a phase 1 clinical trial.
  • BACKGROUND: Photodynamic therapy (PDT) is a non-invasive treatment for non-melanoma skin cancer.
  • STUDY DESIGN/MATERIALS AND METHODS: Forty three adults with a diagnosis of neoplasms including actinic keratoses, Bowen's disease, squamous cell carcinoma, basal cell carcinoma, or mycosis fungoides were treated with a single administration of Pc 4-PDT and followed for 14 days.
  • It has promising biologic effects, particularly in mycosis fungoides where 14 of 35 subjects demonstrated a clinical response, which correlates with Pc 4-PDT-induced apoptosis, as measured by increased active caspase-3 in the treated skin lesions.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Wiley-Liss, Inc.
  • [Cites] Arch Oral Biol. 1998 Feb;43(2):143-9 [9602293.001]
  • [Cites] Photochem Photobiol. 1997 Mar;65(3):581-6 [9077144.001]
  • [Cites] J Am Acad Dermatol. 1999 Mar;40(3):418-25 [10071312.001]
  • [Cites] Am J Public Health. 1999 Aug;89(8):1240-4 [10432915.001]
  • [Cites] Arch Dermatol. 2005 Mar;141(3):305-11 [15781671.001]
  • [Cites] Blood. 2005 May 15;105(10):3768-85 [15692063.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2006 Oct;22(5):254-8 [16948827.001]
  • [Cites] Br J Dermatol. 2006 Nov;155(5):1029-36 [17034536.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):125-43 [17190630.001]
  • [Cites] Biochim Biophys Acta. 2007 Sep;1776(1):86-107 [17693025.001]
  • [Cites] Photochem Photobiol. 2008 Mar-Apr;84(2):407-14 [18221452.001]
  • [Cites] Photochem Photobiol Sci. 2009 Aug;8(8):1111-6 [19639112.001]
  • [Cites] Toxicol Appl Pharmacol. 2009 Dec 1;241(2):163-72 [19695274.001]
  • [Cites] Dermatol Surg. 2000 Aug;26(8):765-9; discussion 769-70 [10940064.001]
  • [Cites] J Invest Dermatol. 2000 Dec;115(6):1041-6 [11121139.001]
  • [Cites] Exp Cell Res. 2001 Feb 1;263(1):145-55 [11161713.001]
  • [Cites] Acta Derm Venereol. 2001 Jun-Jul;81(3):184-8 [11558874.001]
  • [Cites] Cancer Lett. 2002 May 8;179(1):43-9 [11880181.001]
  • [Cites] Arch Dermatol. 2002 Mar;138(3):325-32 [11902983.001]
  • [Cites] Clin Exp Dermatol. 2002 Sep;27(6):493-7 [12372093.001]
  • [Cites] Eur J Med Res. 2002 Nov 25;7(11):477-9 [12568975.001]
  • [Cites] Photochem Photobiol Sci. 2002 Jan;1(1):1-21 [12659143.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] J Am Acad Dermatol. 1989 Mar;20(3):416-28 [2537348.001]
  • [Cites] J Am Acad Dermatol. 1990 May;22(5 Pt 1):802-10 [2347966.001]
  • [Cites] Photochem Photobiol. 1999 Feb;69(2):236-41 [10048316.001]
  • (PMID = 21246576.001).
  • [ISSN] 1096-9101
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / UL1 RR024989; United States / NIAMS NIH HHS / AR / P30 AR039750; United States / NIAMS NIH HHS / AR / AR39750; United States / NIAMS NIH HHS / AR / P30 AR039750-19; United States / NCRR NIH HHS / RR / M01 RR00080; United States / NIAMS NIH HHS / AR / P30 AR039750-18; United States / NCI NIH HHS / CA / P01 CA48735; United States / NIAMS NIH HHS / AR / AR039750-20; United States / NIAMS NIH HHS / AR / P30 AR039750-20; United States / NIAMS NIH HHS / AR / AR039750-18; United States / NCI NIH HHS / CA / P01 CA048735; United States / NCRR NIH HHS / RR / M01 RR000080
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indoles; 0 / Organosilicon Compounds; 0 / Photosensitizing Agents; 135719-28-7 / silicon phthalocyanine
  • [Other-IDs] NLM/ NIHMS314763; NLM/ PMC3149858
  •  go-up   go-down


73. Quatresooz P, Piérard GE, Paquet P, Blaise G, Piérard-Franchimont C: [Cutaneous cancers after organ transplantation]. Rev Med Liege; 2007 Nov;62(11):663-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Cancers cutanés après transplantation d'organe, un revers de médaille.
  • Cutaneous carcinomas are the most frequent malignancies developing after organ transplantation.
  • The usual squamous to basal cell carcinoma ratio is increased and reversed compared to the general population.
  • Carcinomas primarily result from the combination of cumulative sun exposure, fair skin phototype and effects of immunosuppressive drugs.
  • The severity of these carcinomas is due to their multiplicity and to the occurrence of more aggressive lesions.
  • The treatment of the neoplastic lesions is based on their early and complete excision with histological control of the nature of the neoplasm, the safety surgical margins, and the determination of prognostic factors.
  • [MeSH-major] Immunosuppression / adverse effects. Immunosuppressive Agents / adverse effects. Organ Transplantation. Skin Neoplasms / etiology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18217642.001).
  • [ISSN] 0370-629X
  • [Journal-full-title] Revue médicale de Liège
  • [ISO-abbreviation] Rev Med Liege
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  • [Number-of-references] 43
  •  go-up   go-down


74. Lim P, Paver R, Peñas PF: Mohs micrographic surgery at the Skin and Cancer Foundation Australia, 10 years later (1997 vs 2007). J Am Acad Dermatol; 2010 Nov;63(5):832-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mohs micrographic surgery at the Skin and Cancer Foundation Australia, 10 years later (1997 vs 2007).
  • OBJECTIVE: We sought to evaluate changes over time in the type of patients and skin cancers that are treated using MMS, and the repairs used to close the defects.
  • METHODS: We conducted a retrospective study on patients treated with MMS at the Skin and Cancer Foundation Australia, Westmead, in 1997 against those treated in 2007.
  • Patient demographics (age, sex), pathology of tumor, anatomic site of the tumor, preoperative tumor size, postoperative defect size, and repair method were analyzed.
  • The 2007 cohort was a little older (62 vs 64 years), but there were no differences in sex, anatomic site, rate of basal/squamous cell carcinoma, squamous cell carcinoma histologic subtypes, or preoperative tumor size.
  • However, there were fewer superficial basal cell carcinomas, and the postoperative defect size was smaller in 2007 (P < .0001).
  • CONCLUSION: Although tumor size and the percentage of tumors in each anatomic site did not change over 10 years, the size of the defect created after MMS has become smaller.
  • This reduction in defect size may explain why more defects are now repaired by side-to-side closure and flap repairs whereas fewer defects are repaired by skin grafting.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Mohs Surgery / statistics & numerical data. Mohs Surgery / utilization. Skin Neoplasms / surgery
  • [MeSH-minor] Aged. Australia / epidemiology. Cohort Studies. Female. Humans. Male. Middle Aged. Retrospective Studies. Skin Transplantation / statistics & numerical data. Skin Transplantation / utilization. Surgical Flaps / statistics & numerical data. Surgical Flaps / utilization

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20950738.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Pons M, Quintanilla M: Molecular biology of malignant melanoma and other cutaneous tumors. Clin Transl Oncol; 2006 Jul;8(7):466-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular biology of malignant melanoma and other cutaneous tumors.
  • Skin cancer is the most common cancer worldwide.
  • In this review, we summarize the most important genetic changes contributing to the development of malignant melanoma, basal cell carcinoma and squamous cell carcinoma, the main tumor entities arising in the skin.
  • While our understanding of the oncogenes and tumor suppressor genes involved in the development and progression of skin tumors is still fragmentary, recent advances have shown alterations affecting conserved signalling pathways that control cellular proliferation and viability.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Cell Transformation, Neoplastic. Genes, Tumor Suppressor. Melanoma / pathology. Oncogenes. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2002 May;2(5):361-72 [12044012.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13312-7 [11606789.001]
  • [Cites] J Natl Cancer Inst. 2000 Jun 21;92(12):1006-10 [10861313.001]
  • [Cites] N Engl J Med. 2005 Nov 24;353(21):2262-9 [16306523.001]
  • [Cites] Mutat Res. 2005 Apr 1;571(1-2):65-79 [15748639.001]
  • [Cites] Am J Med Genet C Semin Med Genet. 2004 Nov 15;131C(1):82-92 [15468170.001]
  • [Cites] J Cutan Pathol. 2005 Mar;32(3):191-205 [15701081.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1285-91 [10545995.001]
  • [Cites] Nat Genet. 1996 Sep;14 (1):78-81 [8782823.001]
  • [Cites] Lancet. 2002 Jan 5;359(9300):7-8 [11809177.001]
  • [Cites] Int J Dermatol. 2003 Sep;42(9):669-76 [12956675.001]
  • [Cites] Pediatrics. 2004 Apr;113(4 Suppl):1114-9 [15060207.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):559-70 [12894244.001]
  • [Cites] Cancer Metastasis Rev. 1999;18(2):261-84 [10728988.001]
  • [Cites] Cancer Lett. 2005 Jul 28;225(2):181-92 [15978322.001]
  • [Cites] Semin Cancer Biol. 2004 Feb;14(1):63-9 [14757536.001]
  • [Cites] Cancer Cell. 2005 Dec;8(6):439-41 [16338657.001]
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1657-67 [15905207.001]
  • [Cites] Cancer Lett. 2005 Dec 18;230(2):153-86 [16297704.001]
  • [Cites] J Invest Dermatol. 2004 May;122(5):1284-92 [15140233.001]
  • [Cites] Br J Dermatol. 2005 Jun;152(6):1108-24 [15948971.001]
  • [Cites] Mutat Res. 2005 Apr 1;571(1-2):43-56 [15748637.001]
  • [Cites] Nature. 1994 Dec 22-29;372(6508):773-6 [7997263.001]
  • (PMID = 16870533.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Italy
  • [Number-of-references] 23
  •  go-up   go-down


76. Okuyama R, Tagami H, Aiba S: Notch signaling: its role in epidermal homeostasis and in the pathogenesis of skin diseases. J Dermatol Sci; 2008 Mar;49(3):187-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Notch signaling: its role in epidermal homeostasis and in the pathogenesis of skin diseases.
  • Skin undergoes self-renewal throughout life.
  • Terminally differentiated keratinocytes, namely the corneocytes, are continually shed from the surface of the skin, whereas immature cells produce progeny that proceed through the differentiation process.
  • Notch signaling controls a number of cellular processes including cell fate decision, proliferation, differentiation and survival/apoptosis.
  • Hence, Notch and its ligands are expressed in multiple tissues including the skin, where they are abundantly expressed in the epidermis.
  • Notch activation results in the promotion of growth arrest and the onset of differentiation, therefore suggesting that specific Notch activation may regulate skin homeostasis by balancing these processes, i.e.
  • Notch signaling functions as a molecular switch that controls the transition of cells between skin layers during the epidermal differentiation process.
  • Recent advances in the study of Notch signaling have confirmed that there is cross-talk between the Notch signaling pathway and a variety of other signaling molecules including Sonic hedgehog (Shh), beta-catenin and the p53 family member, p63.
  • In addition, Notch counteracts the action of p63 to maintain immature cell characteristics.
  • However, aberrant Notch signaling results in the development of psoriasis and skin cancers such as squamous cell carcinoma, basal cell carcinoma and malignant melanoma.
  • Future efforts to further define how Notch controls cell proliferation and differentiation may lead to the application of Notch in new therapies for various skin diseases.
  • [MeSH-major] Receptors, Notch / physiology. Signal Transduction / physiology. Skin / cytology. Skin Diseases / etiology
  • [MeSH-minor] Animals. Cell Differentiation. Cell Proliferation. Homeostasis. Humans. Langerhans Cells / physiology. Melanocytes / physiology

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17624739.001).
  • [ISSN] 0923-1811
  • [Journal-full-title] Journal of dermatological science
  • [ISO-abbreviation] J. Dermatol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Receptors, Notch
  • [Number-of-references] 67
  •  go-up   go-down


77. Tran KT, Lamb P, Deng JS: Matrikines and matricryptins: Implications for cutaneous cancers and skin repair. J Dermatol Sci; 2005 Oct;40(1):11-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrikines and matricryptins: Implications for cutaneous cancers and skin repair.
  • Dermatologists are faced daily with the need to optimize skin repair and excise cutaneous cancers.
  • The extracellular matrix plays a pivotal role in cellular migration, proliferation, and gene regulation during wound healing and progression of melanoma, basal cell carcinoma, and squamous cell carcinoma.
  • Within the last few years, a new class of ligand, the matrikine or matricryptin, has been characterized as subdomains of various ECM proteins capable of signaling to the cell through receptors, such as growth factor receptors.
  • The EGF-like repeats of tenascin-C and laminin-5 signal to EGFR preferentially to upregulate migration during skin repair and tumor progression.
  • Within the next few years, the nature and function of this emerging class of matrikine ligands will have an impact on dermatology, as these proteins are altered in wound repair and skin diseases.
  • [MeSH-major] Extracellular Matrix Proteins / physiology. Skin Neoplasms / etiology
  • [MeSH-minor] Amino Acid Sequence. Animals. Cell Adhesion Molecules / physiology. Collagen / physiology. Humans. Ligands. Molecular Sequence Data. Signal Transduction. Tenascin / physiology. Tissue Engineering. Wound Healing

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15993569.001).
  • [ISSN] 0923-1811
  • [Journal-full-title] Journal of dermatological science
  • [ISO-abbreviation] J. Dermatol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / Extracellular Matrix Proteins; 0 / Ligands; 0 / Tenascin; 0 / kalinin; 9007-34-5 / Collagen
  • [Number-of-references] 50
  •  go-up   go-down


78. Miller KL, Karagas MR, Kraft P, Hunter DJ, Catalano PJ, Byler SH, Nelson HH: XPA, haplotypes, and risk of basal and squamous cell carcinoma. Carcinogenesis; 2006 Aug;27(8):1670-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] XPA, haplotypes, and risk of basal and squamous cell carcinoma.
  • Nucleotide excision repair (NER) is instrumental in removing DNA lesions caused by ultraviolet (UV) radiation, the dominant risk factor for keratinocyte carcinoma, including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
  • We evaluated whether BCC or SCC risk was influenced by the A23G single nucleotide polymorphism (SNP) in Xeroderma pigmentosum group A (XPA), which codes for an essential protein in NER.
  • We also investigated whether haplotypes of XPA, determined by seven haplotype-tagging SNPs, better define susceptibility to keratinocyte carcinoma.
  • Incident cases of BCC and SCC from New Hampshire were identified through dermatologists and pathology laboratories.
  • Cases of BCC (886) and of SCC (682) were compared with controls (796).
  • Using GG as the reference, the A allele was less frequent among cases of BCC (OR(AG) = 0.82, 95% CI (0.66, 1.01); OR(AA)= 0.74, 95% CI (0.53, 1.03); trend test P = 0.03) and SCC (OR(AG) = 0.85, 95% CI (0.67, 1.07); OR(AA) = 0.74, 95% CI (0.52, 1.05); trend test P = 0.05) than controls.
  • Risk from > or =3 severe sunburns was elevated for those with the GG genotype only, and this interaction was nearly significant for BCC (P = 0.07).
  • Using a haplotype analysis identifying seven common XPA haplotypes indicated that the A23G polymorphism alone captured the differences in susceptibility to keratinocyte carcinoma.
  • The common G allele of the A23G polymorphism was associated with an increased risk of BCC and SCC and this polymorphism appeared to be the determining polymorphism in XPA that alters cancer susceptibility.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Carcinoma, Squamous Cell / genetics. Haplotypes / genetics. Skin Neoplasms / genetics. Xeroderma Pigmentosum Group A Protein / genetics

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16513681.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA006515; United States / NCI NIH HHS / CA / R01 CA082354; United States / NCI NIH HHS / CA / R01CA57494; United States / NIEHS NIH HHS / ES / T32 ES007155
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / XPA protein, human; 0 / Xeroderma Pigmentosum Group A Protein
  •  go-up   go-down


79. Mane DR, Kale AD, Hallikerimath S, Angadi P, Kotrashetti V: Trichilemmal carcinoma associated with xeroderma pigmentosa: report of a rare case. J Oral Sci; 2010 Sep;52(3):505-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trichilemmal carcinoma associated with xeroderma pigmentosa: report of a rare case.
  • Trichilemmal carcinoma is a rare malignant skin adnexal tumor derived from the outer root sheath epithelium of the hair follicle.
  • We describe a rare case of trichilemmal carcinoma of the upper lip associated with xeroderma pigmentosa in a young patient.
  • We demonstrate that this tumor, as well as the more frequently reported squamous cell carcinoma and basal cell carcinoma can occur in association with xeroderma pigmentosa.
  • Making this diagnosis is imperative as the biological behavior of Trichilemmal carcinoma is less aggressive than that of other epithelial malignancies, requiring a different approach to treatment planning.
  • [MeSH-major] Carcinoma, Skin Appendage / complications. Facial Neoplasms / complications. Hair Follicle / pathology. Lip Neoplasms / complications. Xeroderma Pigmentosum / complications
  • [MeSH-minor] Adult. Consanguinity. Diagnosis, Differential. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20881348.001).
  • [ISSN] 1880-4926
  • [Journal-full-title] Journal of oral science
  • [ISO-abbreviation] J Oral Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


80. Han A, Penrose C, Goldsmith A, Marmur ES: Case-based considerations in the treatment of actinic keratoses: utilizing combination or sequential therapy with 5-fluorouracil cream and destructive treatments. J Drugs Dermatol; 2010 Jul;9(7):864-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Actinic keratoses are premalignant lesions that increase in frequency with each decade of life and have the potential to progress to squamous cell carcinoma.
  • Non-melanoma skin cancers, such as squamous cell carcinoma and basal cell carcinoma, also represent sun-related conditions that require early and aggressive treatment.
  • The following case-based review represents typical situations where multiple treatments were combined to manage actinic keratosis, squamous cell carcinoma and basal cell carcinoma in patients over an extended treatment period.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Fluorouracil / administration & dosage. Keratosis, Actinic / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Cryotherapy. Female. Humans. Male. Middle Aged. Photochemotherapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20677546.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


81. Henning JS, Firoz BF: Combat dermatology: the prevalence of skin disease in a deployed dermatology clinic in Iraq. J Drugs Dermatol; 2010 Mar;9(3):210-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combat dermatology: the prevalence of skin disease in a deployed dermatology clinic in Iraq.
  • This paper outlines the prevalence of skin disease among deployed service men and women in Operation Iraqi Freedom.
  • Eight percent (n=205) of the total visits were for skin cancer.
  • This included: basal cell carcinoma, squamous cell carcinoma both in-situ and invasive, mycosis fungoides and melanoma.
  • CONCLUSION: This is the largest publication of the prevalence of skin disease in an exclusively dermatologic clinic in a combat setting.
  • For the first time the presence of skin cancer is noted in a combat setting.
  • [MeSH-major] Military Personnel. Skin Diseases / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Eczema / epidemiology. Female. Humans. Iraq War, 2003-2011. Male. Middle Aged. Prevalence. Skin Diseases, Infectious / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • MedlinePlus Health Information. consumer health - Veterans and Military Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20232580.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Dim-Jamora KC, Perone JB: Management of cutaneous tumors with mohs micrographic surgery. Semin Plast Surg; 2008 Nov;22(4):247-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We discuss the use of Mohs micrographic surgery for the following cutaneous tumors: basal cell carcinoma, squamous cell carcinoma, melanoma in situ, dermatofibrosarcoma protuberans, Merkel cell carcinoma, microcystic adnexal carcinoma, atypical fibroxanthoma, and sebaceous carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1996 Mar 16;347(9003):735-8 [8602006.001]
  • [Cites] J Am Acad Dermatol. 1996 Jul;35(1):82-7 [8682970.001]
  • [Cites] J Am Acad Dermatol. 1995 Feb;32(2 Pt 1):233-6 [7829708.001]
  • [Cites] Lancet. 1994 Feb 19;343(8895):433-4 [7905951.001]
  • [Cites] Cancer. 1994 Jun 15;73(12):2964-70 [8199993.001]
  • [Cites] Clin Plast Surg. 1993 Jan;20(1):149-56 [8420703.001]
  • [Cites] J Am Acad Dermatol. 1993 Nov;29(5 Pt 2):840-5 [8408823.001]
  • [Cites] Otolaryngol Clin North Am. 1993 Apr;26(2):185-202 [8460037.001]
  • [Cites] J Dermatol Surg Oncol. 1991 Aug;17(8):681-4 [1885833.001]
  • [Cites] Dermatol Clin. 1989 Oct;7(4):833-43 [2676291.001]
  • [Cites] Dermatol Clin. 1989 Oct;7(4):609-11 [2676280.001]
  • [Cites] J Dermatol Surg Oncol. 1989 Mar;15(3):315-28 [2646336.001]
  • [Cites] N J Med. 1989 May;86(5):369-73 [2739948.001]
  • [Cites] J Am Acad Dermatol. 1986 Apr;14(4):668-73 [3958277.001]
  • [Cites] Eye (Lond). 1990;4 ( Pt 1):160-8 [2323467.001]
  • [Cites] Head Neck Surg. 1983 Jan-Feb;5(3):197-203 [6841116.001]
  • [Cites] Arch Dermatol. 1974 Aug;110(2):231-2 [4853214.001]
  • [Cites] Plast Reconstr Surg. 2004 Jun;113(7):2233; author reply 2233-4 [15253235.001]
  • [Cites] Arch Dermatol. 2004 Jun;140(6):736-42 [15210467.001]
  • [Cites] Clin Plast Surg. 2004 Jan;31(1):5-31 [15022790.001]
  • [Cites] Plast Reconstr Surg. 2002 Nov;110(6):1601 [12409793.001]
  • [Cites] Dermatol Surg. 2002 Aug;28(8):656-65 [12174054.001]
  • [Cites] Semin Oncol. 2002 Aug;29(4):336-40 [12170436.001]
  • [Cites] Dermatol Surg. 2002 Jul;28(7):623-31 [12135523.001]
  • [Cites] Br J Dermatol. 2002 Jan;146(1):18-25 [11841362.001]
  • [Cites] J Am Acad Dermatol. 2001 Oct;45(4):579-86 [11568750.001]
  • [Cites] Arch Facial Plast Surg. 2001 Jul-Sep;3(3):202-6 [11497507.001]
  • [Cites] J Am Acad Dermatol. 2001 Jun;44(6):1004-9 [11369914.001]
  • [Cites] Dermatol Surg. 2001 Apr;27(4):401-8 [11298716.001]
  • [Cites] Dermatol Surg. 2000 Aug;26(8):771-84 [10940065.001]
  • [Cites] Dermatol Surg. 2000 Apr;26(4):303-7 [10759814.001]
  • [Cites] Aust N Z J Surg. 2000 May;70(5):358-61 [10830600.001]
  • [Cites] Cancer. 2000 Apr 15;88(8):1842-51 [10760761.001]
  • [Cites] Dermatol Surg. 2007 Apr;33(4):395-402 [17430372.001]
  • [Cites] Skin Therapy Lett. 2007 Mar;12(2):6-9 [17393051.001]
  • [Cites] Ophthalmology. 2007 Jan;114(1):187-92 [17140665.001]
  • [Cites] Arch Dermatol. 2006 Feb;142(2):187-94 [16490846.001]
  • [Cites] Dermatol Surg. 2005 Nov;31(11 Pt 1):1428-33 [16416612.001]
  • [Cites] Dermatol Surg. 2005 Sep;31(9 Pt 1):1094-9; discussion 1100 [16164856.001]
  • [Cites] Curr Surg. 2005 Sep-Oct;62(5):518-26 [16125611.001]
  • [Cites] Arch Facial Plast Surg. 2005 Sep-Oct;7(5):342-6 [16172346.001]
  • [Cites] J Craniofac Surg. 2005 May;16(3):439-43 [15915111.001]
  • [Cites] Dermatol Surg. 2005 Jan;31(1):10-5 [15720088.001]
  • [Cites] Dermatol Surg. 2004 Dec;30(12 Pt 1):1479-85 [15606735.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1766-72 [15541449.001]
  • [Cites] Am J Otolaryngol. 2004 Nov-Dec;25(6):385-93 [15547806.001]
  • [Cites] J Am Acad Dermatol. 1998 Nov;39(5 Pt 1):698-703 [9810885.001]
  • [Cites] Semin Cutan Med Surg. 1998 Jun;17(2):80-95 [9669602.001]
  • [Cites] J Am Acad Dermatol. 1998 Jul;39(1):79-97 [9674401.001]
  • [Cites] Dermatol Surg. 1997 Nov;23(11):1061-6 [9391565.001]
  • [Cites] Dermatol Surg. 1997 Oct;23(10):929-33 [9357504.001]
  • [Cites] Dermatol Surg. 1997 Feb;23(2):105-10 [9107284.001]
  • [Cites] J Am Acad Dermatol. 1995 Jul;33(1):1-15; quiz 16-8 [7601925.001]
  • (PMID = 20567701.001).
  • [ISSN] 1536-0067
  • [Journal-full-title] Seminars in plastic surgery
  • [ISO-abbreviation] Semin Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2884874
  • [Keywords] NOTNLM ; Mohs micrographic surgery / cutaneous oncology / skin cancer
  •  go-up   go-down


83. Hantash BM, Stewart DB, Cooper ZA, Rehmus WE, Koch RJ, Swetter SM: Facial resurfacing for nonmelanoma skin cancer prophylaxis. Arch Dermatol; 2006 Aug;142(8):976-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Facial resurfacing for nonmelanoma skin cancer prophylaxis.
  • OBJECTIVE: To determine the effect of facial skin resurfacing for treatment of actinic keratoses (AKs) and prophylaxis against new primary basal and squamous cell carcinomas in individuals with previous nonmelanoma skin cancer (NMSC) or severe photodamage.
  • SETTING: Dermatology and otolaryngology clinics of a Veterans Affairs hospital.
  • PATIENTS: Thirty-four patients with a history of facial or scalp AKs or basal or squamous cell carcinoma were enrolled.
  • Times from baseline to diagnosis of first skin cancer were compared between the treatment and control groups.
  • RESULTS: Treatment with fluorouracil, trichloroacetic acid, or carbon dioxide laser resulted in an 83% to 92% reduction in AKs (P< or =.03), a lower incidence of NMSC compared with the control group (P<.001), and a trend toward longer time to development of new skin cancer compared with the control group (P=.07).
  • CONCLUSION: All 3 modalities demonstrated benefit for AK reduction and skin cancer prophylaxis compared with controls and warrant further study in a larger trial.
  • [MeSH-major] Keratolytic Agents / administration & dosage. Keratosis / prevention & control. Low-Level Light Therapy. Skin Neoplasms / prevention & control
  • [MeSH-minor] Aged. Aged, 80 and over. Carbon Dioxide. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / prevention & control. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / prevention & control. Disease-Free Survival. Drug Administration Schedule. Face. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Prospective Studies. Scalp. Severity of Illness Index. Treatment Outcome. Trichloroacetic Acid / administration & dosage


84. Tanahashi J, Kashima K, Daa T, Yada N, Fujiwara S, Yokoyama S: Merkel cell carcinoma co-existent with sebaceous carcinoma of the eyelid. J Cutan Pathol; 2009 Sep;36(9):983-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma co-existent with sebaceous carcinoma of the eyelid.
  • Merkel cell carcinoma is occasionally associated with other types of cutaneous malignancies including squamous cell carcinoma, basal cell carcinoma and lentigo maligna.
  • We report a case of Merkel cell carcinoma co-existent with sebaceous carcinoma in the right upper eyelid of a 61-year-old Japanese man.
  • Histopathologically, the resected tumor consisted of three nodules located in the tarsal plate, showing two distinct histopathological types.
  • Two nodules were Merkel cell carcinoma and located in the proximal part of the palpebral conjunctiva.
  • The third was sebaceous carcinoma located in the distal transitional zone between the epidermis and the conjunctiva.
  • Metastatic deposits were identified in the regional lymph nodes, which solely consisted of Merkel cell carcinoma without sebaceous carcinoma.
  • [MeSH-major] Adenocarcinoma, Sebaceous / pathology. Carcinoma, Merkel Cell / pathology. Eyelid Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Sebaceous Gland Neoplasms / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19017040.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


85. Heal C, Buettner P, Raasch B, Browning S: Minor skin excisions in general practice in North Queensland. Aust Fam Physician; 2006 Oct;35(10):825-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minor skin excisions in general practice in North Queensland.
  • OBJECTIVE: To describe the demographics of patients presenting with skin cancer to general practitioners in rural North Queensland, the sites from which skin cancers are removed, and their histology.
  • METHODS: Data was recorded from 1247 consecutive patients who attended for minor skin lesion excisions.
  • RESULTS: Close to half (46.7%) of lesions excised were skin cancers.
  • We excised more squamous cell carcinomas than basal cell carcinomas (0.74:1).
  • Mean age for excision of melanoma, basal cell carcinoma and squamous cell carcinoma was 55, 60.9 and 63.8 years respectively.
  • Relative tumour density was greatest in the face, scalp and neck region for all skin cancers.
  • DISCUSSION: In this sample of Mackay GPs, there was a very high yield of skin cancers from all excisions.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Family Practice. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17019461.001).
  • [ISSN] 0300-8495
  • [Journal-full-title] Australian family physician
  • [ISO-abbreviation] Aust Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


86. Szeimies RM, Karrer S: Towards a more specific therapy: targeting nonmelanoma skin cancer cells. Br J Dermatol; 2006 May;154 Suppl 1:16-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Towards a more specific therapy: targeting nonmelanoma skin cancer cells.
  • Epithelial cancers of the skin, e.g. basal cell carcinoma and squamous cell carcinoma, are the most common tumours in humans with increasing incidence.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / therapy. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16712712.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 20
  •  go-up   go-down


87. Ben Simon GJ, Schwarcz RM, Douglas R, Fiaschetti D, McCann JD, Goldberg RA: Orbital exenteration: one size does not fit all. Am J Ophthalmol; 2005 Jan;139(1):11-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnosis included orbital, ocular, and adnexal malignancies, with squamous and basal cell carcinoma being the most common.
  • During follow-up period 3 patients expired, only 1 of which was tumor-related.
  • CONCLUSIONS: Clinical indications for orbital exenteration remain similar over the last four decades with a higher prevalence of squamous cell carcinoma in our institute.
  • Orbital exenteration is considered curative in cases of basal or squamous cell carcinoma but not in cases of malignant infiltrative processes such as adenoid cystic carcinoma of the lacrimal gland.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Ophthalmol. 2005 Jan;139(1):152-3 [15652840.001]
  • (PMID = 15652823.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Chren MM, Sahay AP, Bertenthal DS, Sen S, Landefeld CS: Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol; 2007 Jun;127(6):1351-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma.
  • Quality of life is an important treatment outcome for conditions that are rarely fatal, such as cutaneous basal cell carcinoma and squamous cell carcinoma (typically called nonmelanoma skin cancer (NMSC)).
  • The main outcome was tumor-related quality of life 1 to 2 years after therapy, measured with the 16-item version of Skindex, a validated measure.
  • [MeSH-major] Carcinoma, Basal Cell / psychology. Carcinoma, Basal Cell / surgery. Quality of Life. Skin Neoplasms / psychology. Skin Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Squamous Cell / psychology. Carcinoma, Squamous Cell / surgery. Emotions. Female. Follow-Up Studies. Health Status Indicators. Humans. Male. Middle Aged. Mohs Surgery. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17301830.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / K02 AR 02203-01
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


89. Tran TA, Muller S, Chaudahri PJ, Carlson JA: Cutaneous carcinosarcoma: adnexal vs. epidermal types define high- and low-risk tumors. Results of a meta-analysis. J Cutan Pathol; 2005 Jan;32(1):2-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous carcinosarcoma: adnexal vs. epidermal types define high- and low-risk tumors. Results of a meta-analysis.
  • RESULTS: CS occurred in elderly patients (mean of 80 years) on sun-damaged skin, and were keratotic papules of short duration.
  • CS exhibited basal cell carcinoma mixed with atypical fibroxanthoma cell populations.
  • Epidermal-derived (basal or squamous cell carcinoma epithelial component) CS arose on the sun-damaged skin of the head and neck of elderly males (mean age 72 years) and had a 70% 5-year disease-free survival.
  • In contrast, adnexal CS (spiradenocarcinoma, porocarcinoma, proliferating tricholemmal cystic carcinoma, or matrical carcinoma) occurred in younger patients (mean age 58 years), showed recent growth in a long-standing nodule and had a 25% 5-year disease-free survival.
  • Age less than 65 years, recent growth, long-standing skin tumor, and tumor size greater than 2 cm significantly correlated with poor outcome.
  • CONCLUSIONS: Cutaneous CS is an aggressive skin cancer with high risk for advanced disease.
  • [MeSH-major] Carcinosarcoma / pathology. Epithelial Cells / pathology. Neoplasms, Adnexal and Skin Appendage / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Carcinoma, Basal Cell / classification. Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / classification. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Diagnosis, Differential. Female. Humans. Male. PubMed. Survival Rate

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15660649.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Meta-Analysis
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


90. Sun J, Gui X, He J, Liu HM, Yu HY, Xia CY, Xu Y: [The relationship between infestation of Demodex folliculorum and epidermal neoplasm on face]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2005 Dec 30;23(6):428-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The relationship between infestation of Demodex folliculorum and epidermal neoplasm on face].
  • OBJECTIVE: To discuss the relationship between infestation of Demodex folliculorum and facial epidermal neoplasm.
  • METHODS: A retrospective analysis was made with the pathological data of 153 cases collected in the recent four years on facial basal cell carcinoma, squamous cell carcinoma, seborrheic keratosis and trichilemmoma.
  • The infection rate of Demodex folliculorum in the four types of neoplasm was evaluated and the relationship between the infection rate and the location of neoplasm and age was analyzed by V2 test.
  • RESULTS: There was a significant difference in the infestation rate of Demodex folliculorum in the four types of epidermal neoplasm(P < 0.05), with the highest rate in basal cell carcinoma(56%), compared with seborrheic keratosis (21%), trichilemmoma (20%), and squamous cell carcinoma (14%).
  • The infestation rate of Demodex folliculorum was significantly different in variant locations of epidermal neoplasm (P < 0.05).
  • The highest infestation rate was in cases of nasal neoplasm (71%), compared with other parts.
  • In addition, among twelve cases of Demodex folliculorum positive nasal neoplasm, nine were basal cell carcinoma; ten of thirty-six basal cell carcinoma occurred on nose.
  • CONCLUSION: The highest infestation rate of Demodex folliculorum was in cases of nasal epidermal neoplasm compared with other locations, and the cases of basal cell carcinoma showed the highest infestation rate among the four types of neoplasm.
  • [MeSH-major] Facial Neoplasms / etiology. Mite Infestations / complications. Skin Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16566213.001).
  • [ISSN] 1000-7423
  • [Journal-full-title] Zhongguo ji sheng chong xue yu ji sheng chong bing za zhi = Chinese journal of parasitology & parasitic diseases
  • [ISO-abbreviation] Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


91. Hatta N, Hirano T, Kimura T, Hashimoto K, Mehregan DR, Ansai S, Takehara K, Takata M: Molecular diagnosis of basal cell carcinoma and other basaloid cell neoplasms of the skin by the quantification of Gli1 transcript levels. J Cutan Pathol; 2005 Feb;32(2):131-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular diagnosis of basal cell carcinoma and other basaloid cell neoplasms of the skin by the quantification of Gli1 transcript levels.
  • BACKGROUND: Distinguishing basal cell carcinoma (BCC) from other benign and malignant skin tumors is sometimes a difficult task for the pathologists.
  • Because the activation of hedgehog signals and the up-regulation of its critical transcriptional factor Gli1 are well documented in BCC, a molecular technique measuring Gli1 transcripts may aide the diagnosis.
  • METHODS: Gli1 transcript levels were measured by real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) using RNA extracted from formalin-fixed, paraffin-embedded tissues of 68 cases of various skin tumors.
  • The tumors included BCC (21), squamous cell carcinoma (13), seborrheic keratoses (8), trichoepithelioma (5), eccrine poroma/porocarcinoma (4), and sebaceous epithelioma/carcinoma (2).
  • In these unambiguous cases, all BCC and trichoepithelioma tumors showed high expression of Gli1mRNA, while the expression was virtually absent in other tumors.
  • The diagnosis was discordant among three pathologists in the remaining 15 tumors.
  • Histological diagnoses included BCC, BCC with sebaceous differentiation, sebaceoma/sebaceous epithelioma, trichoblastoma, trichoepithelioma, basaloid follicular harmartoma, basosquamous carcinoma, etc.
  • CONCLUSIONS: Quantification of Gli1 transcripts by RT-PCR is helpful in discriminating BCC and trichoepithelioma from other skin tumors.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / diagnosis. Oncogene Proteins / metabolism. Skin Neoplasms / diagnosis. Transcription Factors / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Child. Diagnosis, Differential. Female. Humans. Male. Middle Aged. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Trans-Activators. Transcription, Genetic

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15606671.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Gli protein; 0 / Oncogene Proteins; 0 / RNA, Messenger; 0 / Trans-Activators; 0 / Transcription Factors
  •  go-up   go-down


92. Fantini F, Gualdi G, Cimitan A, Giannetti A: Metastatic basal cell carcinoma with squamous differentiation: report of a case with response of cutaneous metastases to electrochemotherapy. Arch Dermatol; 2008 Sep;144(9):1186-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic basal cell carcinoma with squamous differentiation: report of a case with response of cutaneous metastases to electrochemotherapy.
  • BACKGROUND: Metastatic basal cell carcinoma is a rare disease with poor prognosis.
  • Electrochemotherapy is a recently described therapy that relies on the permeation of cancer cell membranes by electrical pulses to enhance cytotoxic drug penetration.
  • It has been successfully used in the treatment of primary and metastatic skin cancers.
  • We report a case of metastatic basal cell carcinoma in which electrochemotherapy was effective in inducing local regression of skin metastases.
  • OBSERVATIONS: A 75-year-old man presented with a pigmented, deeply infiltrating nodule in the right axilla manifesting as basal cell carcinoma with squamous differentiation at histopathologic examination.
  • Three successive sessions of electrochemotherapy with bleomycin sulfate were then performed on isolated skin metastases.
  • Conclusion Electrochemotherapy is an effective and well-tolerated adjunct to the therapeutic options in metastatic basal cell carcinoma, characterized by an advantageous risk-benefit ratio and minimal downtime.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / secondary. Electrochemotherapy. Skin Neoplasms / pathology. Skin Neoplasms / secondary
  • [MeSH-minor] Aged. Antibiotics, Antineoplastic / therapeutic use. Bleomycin / therapeutic use. Cell Differentiation. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18794464.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


93. Ducic Y, Marra DE, Kennard C: Initial Mohs surgery followed by planned surgical resection of massive cutaneous carcinomas of the head and neck. Laryngoscope; 2009 Apr;119(4):774-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial Mohs surgery followed by planned surgical resection of massive cutaneous carcinomas of the head and neck.
  • OBJECTIVE: To review our experience with Mohs excision of massive cutaneous carcinomas for peripheral margin control, followed by planned definitive resection of the deeply invasive component of the carcinoma.
  • METHODS: All cases of massive (at least 10 cm in dimension) cutaneous carcinomas treated by the technique outlined by Yadranko Ducic from 1998-2006.
  • RESULTS: A total of 28 cases (7 squamous cell carcinomas, 14 basal cell carcinomas, 7 basosquamous carcinomas) were treated in this manner.
  • Average maximal tumor dimension was 12.7 cm with a range of 10-21 cm.
  • There were a total of 7 local recurrences (5 squamous cell carcinoma and 2 basal cell carcinoma).
  • CONCLUSIONS: The technique appears to be an excellent means of treatment of massive, neglected, and deeply invasive cutaneous carcinomas of the face and neck.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Basosquamous / surgery. Carcinoma, Squamous Cell / surgery. Head and Neck Neoplasms / surgery. Mohs Surgery / methods. Neoplasm Recurrence, Local / surgery. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19205010.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Nashan D, Radny P, Kösters NC, Nashan B: [Skin tumors in organ-transplant recipients]. Hautarzt; 2007 Jan;58(1):48-50, 52-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Skin tumors in organ-transplant recipients].
  • Skin cancers are a significant medical problem for organ-transplant recipients.
  • Squamous cell carcinoma and basal cell carcinoma are most common tumors.
  • An increasing incidence of melanoma, Kaposi sarcoma, Merkel cell carcinoma, as well as uncommon skin malignancies, is also seen.
  • Predisposing factors include cumulative sun exposure, cumulative immunosuppression, age, gender, skin type, virus detection and genetic alterations.
  • Skin tumors grow rapidly and their number continues to increase in the years following transplantation.
  • Large numbers of tumors, aggressive courses and appearance in young patients are other characteristics of these skin tumors.
  • In addition standardized registries are needed to assure the comparability of data, to better correlate immunosuppression with skin tumors and to plan therapeutic studies.
  • [MeSH-major] Carcinoma / epidemiology. Melanoma / epidemiology. Risk Assessment / methods. Skin Neoplasms / epidemiology. Transplants / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Derm Venereol. 1992;72(2):115-9 [1350395.001]
  • [Cites] Transplant Proc. 1999 Sep;31(6):2317-8 [10500596.001]
  • [Cites] Transplant Proc. 1995 Aug;27(4):2450-1 [7652877.001]
  • [Cites] Transplant Proc. 1996 Apr;28(2):876-8 [8623443.001]
  • [Cites] Arch Dermatol. 2005 Aug;141(8):978-82 [16103326.001]
  • [Cites] Br J Dermatol. 1993 Sep;129(3):242-9 [8286220.001]
  • [Cites] Science. 2005 Sep 16;309(5742):1871-4 [16166520.001]
  • [Cites] Circulation. 2000 Nov 7;102(19 Suppl 3):III222-7 [11082391.001]
  • [Cites] Lancet. 1997 Oct 25;350(9086):1193-8 [9652559.001]
  • [Cites] JAMA. 2005 Sep 28;294(12):1476-80 [16189357.001]
  • [Cites] Nephron. 1996;73(2):131-6 [8773333.001]
  • [Cites] Transplant Proc. 1999 Feb-Mar;31(1-2):1260-2 [10083562.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1681-91 [12711744.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1758-64 [10223570.001]
  • [Cites] J Am Acad Dermatol. 1999 Feb;40(2 Pt 1):177-86 [10025742.001]
  • [Cites] J Am Acad Dermatol. 1999 Jan;40(1):27-34 [9922009.001]
  • [Cites] Transplant Proc. 2005 Mar;37(2):962-3 [15848591.001]
  • [Cites] Cutis. 2004 Nov;74(5 Suppl):4-9 [15603215.001]
  • [Cites] Arch Dermatol. 2003 Mar;139(3):301-6 [12622621.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):642-50 [15061849.001]
  • [Cites] Am J Kidney Dis. 2000 Jul;36(1):167-76 [10873887.001]
  • [Cites] N Engl J Med. 2005 Mar 31;352(13):1317-23 [15800227.001]
  • [Cites] Arch Dermatol. 1986 Nov;122(11):1288-93 [3535683.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):604-9 [15061843.001]
  • [Cites] Transplant Proc. 1998 Sep;30(6):2768-70 [9745563.001]
  • [Cites] Transplant Proc. 1994 Oct;26(5):2493-8 [7940765.001]
  • [Cites] Transpl Int. 2004 Jul;17(6):279-85 [15221123.001]
  • [Cites] Transplantation. 1996 Mar 15;61(5):715-21 [8607173.001]
  • [Cites] Hautarzt. 2002 Aug;53(8):524-33 [12221466.001]
  • [Cites] Transplant Proc. 1999 Feb-Mar;31(1-2):1120 [10083500.001]
  • [Cites] Lancet. 1998 Feb 28;351(9103):623-8 [9500317.001]
  • (PMID = 16758224.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 33
  •  go-up   go-down


95. Snyder RJ: Skin cancers and wounds in the geriatric population: a review. Ostomy Wound Manage; 2009 Apr;55(4):64-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin cancers and wounds in the geriatric population: a review.
  • Diagnosis of wound malignancy often remains elusive and is of particular concern in the geriatric population because the average age for presentation of squamous cell cancer is 70 years.
  • Basal and squamous cell carcinoma, as well as Marjolin's ulcer, may look like a chronic or acute wound, can develop in the wound itself, or be found in the scar tissue of these wounds.
  • A complete patient history should include questions about sun exposure and personal and family history of skin cancer.
  • Some wounds exhibit typical clinical signs of cancer - ie, raised borders, crusting - but many do not, making diagnosis more challenging.
  • An accurate diagnosis is crucial to positive treatment outcomes.
  • [MeSH-major] Skin Neoplasms / complications. Skin Neoplasms / diagnosis. Wounds and Injuries / complications. Wounds and Injuries / diagnosis
  • [MeSH-minor] Acute Disease. Age Factors. Aged. Aging. Biopsy / methods. Causality. Chronic Disease. Diagnosis, Differential. Diagnostic Errors. Humans. Medical History Taking. Patient Selection. Skin Care / methods. Wound Healing

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Wounds and Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19387098.001).
  • [ISSN] 0889-5899
  • [Journal-full-title] Ostomy/wound management
  • [ISO-abbreviation] Ostomy Wound Manage
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 81
  •  go-up   go-down


96. Farley R, Ratner D: Diagnosis and management of atypical fibroxanthoma. Skinmed; 2006 Mar-Apr;5(2):83-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and management of atypical fibroxanthoma.
  • A 90-year-old Caucasian man with a history of basal cell carcinoma and squamous cell carcinoma presented with a friable erythematous nodule on his scalp that had been present for several months.
  • What is your diagnosis?
  • [MeSH-major] Histiocytoma, Benign Fibrous / diagnosis. Scalp. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Humans. Male

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16603840.001).
  • [ISSN] 1540-9740
  • [Journal-full-title] Skinmed
  • [ISO-abbreviation] Skinmed
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 43
  •  go-up   go-down


97. Cabrijan L, Lipozencić J, Batinac T, Lenković M, Stanić Zgombić Z: Influence of PUVA and UVB radiation on expression of ICAM-1 and VCAM-1 molecules in psoriasis vulgaris. Coll Antropol; 2008 Oct;32 Suppl 2:53-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression of adhesion molecules Intercellular adhesion molecule-1 (ICAM-1) and Vascular cell adhesion molecule-1 (VCAM-1) is increased in lesional and in non-lesional skin of psoriatic patients, and play role in pathogenesis of the disease.
  • The expression of these molecules was examined by immunohistochemical method in lesional and non-lesional skin of 10 patients with psoriasis vulgaris before and after treatment.
  • After therapy, the expression of the adhesion molecules decreased together with a marked improvement of the disease.
  • Adverse reactions due to intense or long lasting UVA (PUVA) and UVB therapies are immunosuppression and damage of DNA which can lead to development of non-melanocytic skin tumors like basal cell carcinoma and squamous cell carcinoma, as well as melanoma.
  • [MeSH-major] Intercellular Adhesion Molecule-1 / radiation effects. Psoriasis / metabolism. Psoriasis / therapy. Ultraviolet Therapy. Vascular Cell Adhesion Molecule-1 / radiation effects

  • Genetic Alliance. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Psoriasis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19138007.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Vascular Cell Adhesion Molecule-1; 126547-89-5 / Intercellular Adhesion Molecule-1
  •  go-up   go-down


98. Rizvi SA, Amitava AK, Mehdi G, Sharma R, Alam MS: Orbital amelanotic melanoma in xeroderma pigmentosum: a rare association. Indian J Ophthalmol; 2008 Sep-Oct;56(5):421-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Xeroderma pigmentosum (XP) is an autosomal recessive genetic disorder of DNA repair in which the body's normal ability to repair damage caused by ultraviolet light is deficient.
  • Ocular neoplasms occurring in XP in order of frequency are squamous cell carcinoma, basal cell carcinoma and melanoma.
  • Malignant melanomas occur at an early age in patients with XP.
  • [MeSH-major] Melanoma, Amelanotic / complications. Orbit. Skin Neoplasms / complications. Xeroderma Pigmentosum / complications
  • [MeSH-minor] Child. Diagnosis, Differential. Humans. Male. Ophthalmologic Surgical Procedures / methods

  • Genetic Alliance. consumer health - Xeroderma pigmentosum.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1974 Feb;80(2):221-48 [4811796.001]
  • [Cites] Cancer. 1982 Sep 1;50(5):912-8 [6807528.001]
  • [Cites] Arch Dermatol. 1987 Feb;123(2):241-50 [3545087.001]
  • [Cites] Tunis Med. 2006 Sep;84(9):542-4 [17263199.001]
  • [Cites] Br J Ophthalmol. 1993 Sep;77(9):597-8 [8218060.001]
  • [Cites] Br J Ophthalmol. 1994 Apr;78(4):295-7 [8199117.001]
  • [Cites] Br J Dermatol. 1965 May;77:261-76 [14283428.001]
  • [Cites] Arch Ophthalmol. 1989 Mar;107(3):402-7 [2923565.001]
  • (PMID = 18711275.001).
  • [ISSN] 0301-4738
  • [Journal-full-title] Indian journal of ophthalmology
  • [ISO-abbreviation] Indian J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2636150
  •  go-up   go-down


99. Felder S, Rabinovitz H, Oliviero M, Kopf A: Dermoscopic differentiation of a superficial basal cell carcinoma and squamous cell carcinoma in situ. Dermatol Surg; 2006 Mar;32(3):423-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermoscopic differentiation of a superficial basal cell carcinoma and squamous cell carcinoma in situ.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Dermoscopy. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16640692.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Leonardi CL, Toth D, Cather JC, Langley RG, Werther W, Compton P, Kwon P, Wetherill G, Curtin F, Menter A: A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis. Dermatology; 2006;213(3):204-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Psoriasis is a chronic, incurable immune-mediated disease.
  • The results for the efalizumab-treated patients were compared with the data on psoriasis patients from insurance claims databases and a registry of events in the general population.
  • RESULTS: The efalizumab- and placebo-treated patients had similar incidence rates of malignancy, including lymphoproliferative disease, solid tumor, malignant melanoma and nonmelanoma skin cancer.
  • The incidence of nonmelanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma, in patients receiving efalizumab or placebo was elevated relative to the external databases.
  • The difference observed with nonmelanoma skin cancer may be due to biases introduced by the clinical trial methodology.
  • Additional patient observation is necessary to ascertain whether a link exists between efalizumab therapy and nonmelanoma skin cancer above that normally observed in psoriasis patients.

  • Genetic Alliance. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Psoriasis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17033169.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Comparative Study; Meta-Analysis
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / efalizumab
  •  go-up   go-down






Advertisement